Saturday Program

Simultaneous Sessions | Clinical Trial Update | Science in progress | Hematology-in-focus Session | Lunch Debates | Meet-the-Expert | 5th EHA / ASH Joint Symposium | EHA Business Meeting | Jean Bernard Lifetime Achievement Award | Presidential Symposium | Plenary Session 1 | Poster Session II

POSTER-WALKS

We would like to invite you to the EHA Poster sessions!
This event was introduced to gain maximum benefit from the scientific work presented and to create a lively interaction and discussion between poster authors, moderators and interested delegates.
Poster-walks will be organized during poster sessions on Friday, June 13 (17:45 – 19:00) and Saturday, June 14 (18:00 – 19:15). The poster area is located behind the exhibition. Poster-walk moderators can be recognized by their cap. We kindly ask you to be in time at the first poster in the poster session of your interest. Drinks and Danish snacks will be served.

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY
Poster-walk Moderator: C Mecucci (University of Perugia, Perugia,Italy)

ACUTE MYELOID LEUKEMIA- BIOLOGY II
Poster-walk Moderator: S Izraeli (Sheba Medical Center Tel Hashomer, Ramat Gan, Israel)

ACUTE MYELOID LEUKEMIA - CLINICAL II
Poster-walk Moderator: H Döhner (University Hospital Ulm, Ulm, Germany)

CHRONIC LYMPHOCYTIC LEUKEMIA - PROGNOSTIC FACTORS
Poster-walk Moderator: M Hallek (University of Cologne, Cologne,Germany)

CHRONIC MYELOID LEUKEMIA - CLINICAL II
Poster-walk Moderator: T Lion (Labdia Labordiagnostik Gmbh, Vienna,Austria)

CYTOGENETICS AND MOLECULAR DIAGNOSTICS II
Poster-walk Moderator: A Cuneo (Ospedale Sant Anna, Ferrara, Italy)

EPIGENETICS, TRANSCRIPTION AND SIGNALLING
Poster-walk Moderator: C Nerlov (European Molecular Biology Laboratory, Monterotondo,Italy)

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION
Poster-walk Moderator: F Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)

HODGKIN 'S LYMPHOMA
Poster-walk Moderator: P Jacobs (Constantiaberg Medi Clinic, Capetown, South Africa)

INHERITED ANAEMIAS: SICKLE CELL DISEASE AND RED CELL MEMBRANE DISORDERS
Poster-walk Moderator: W van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)

MULTIPLE MYELOMA – CLINICAL II
Poster-walk Moderator: A Palumbo (Az.Ospedaliera Molinette, Turin, Italy)

MULTIPLE MYELOMA – CLINICAL III
Poster-walk Moderator: J Bladé (Hospital Clinic of Barcelona, Barcelona, Spain)

MYELODYSPLASTIC SYNDROMES - BIOLOGY
Poster-walk Moderator: V Santini (University of Florence, Firenze, Italy)

MYELODYSPLASTIC SYNDROMES - CLINICAL II
Poster-walk Moderator: A Vanucchi (University of Florence, Florence, Italy)

MYELODYSPLASTIC SYNDROMES - DIAGNOSTIC
Poster-walk Moderator: W-K Hofmann (Charite-University Hospital Benjamin Franklin, Berlin, Germany)

MYELOPROLIFERATIVE DISORDERS - BIOLOGY
Poster-walk Moderator: J Reilly (Royal Hallamshire Hospital, Sheffield, United Kingdom)

MYELOPROLIFERATIVE DISORDERS - CLINICAL
Poster-walk Moderator: T Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)

NON-HODGKIN'S LYMPHOMA - CLINICAL (AGGRESSIVE)
Poster-walk Moderator: M van Oers (Academic Medical Center, Amsterdam, The Netherlands)

NOVEL THERAPIES, DRUG RESISTANCE & PHARMACOLOGY II
Poster-walk Moderator: G Martinelli (Inst. of Hematology and Medical Oncology "Seràgnoli", Bologna, Italy)

QUALITY OF LIFE, ETHICS, ECONOMICS
Poster-walk Moderator: F Efficace (Mediterranean Institute of Hematology, Rome, Italy)

STEM CELL TRANSPLANTATION - AUTOLOGOUS/DLI/MISCELLANEOUS
Poster-walk Moderator: J Kuball (University Medical Center Utrecht, Utrecht, The Netherlands)

STEM CELL TRANSPLANTATION - GVHD/GRAFT REJECTION/INFECTION
Poster-walk Moderator: A Gratwohl (University Hospital Basel, Basel, Switzerland)

THALASSEMIA AND IRON OVERLOAD
Poster-walk Moderator: M Cappellini (Università di Milano, Milan, Italy)

THROMBOSIS II
Poster-walk Moderator: H Büller (Academic Medical Center, Amsterdam, The Netherlands)

 

POSTER SESSION II
18:00 – 19:15

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY

0476 LCK IS A CRITICAL SIGNALING EFFECTOR IN NUP214-ABL1 POSITIVE T-ALL
K. De Keersmaecker, M. Porcu, O. Gielen, J. Cools (K.U.Leuven,
Leuven, Belgium)

0477 UNINTENTIONAL TRANSPLANTATION OF T CELL LYMPHOBLASTICLEUKEMIA OF THE DONOR TO THREE DIFFERENT ORGAN RECIPIENTS WITH SIGNIFICANT HLA INCOMPATIBILITIES
W. Jedrzejczak, J. Dwilewicz-Trojaczek, A. Dmoszynska, L. Konopka,
B. Ziarkiewicz-Wroblewska, E. Chmarzynska-Mroz, G. Charlinski,
A. Gronkowska, B. Kaczmarek, H. Stanczak, M. Nowaczyk,
A. Sadowska (Medical University of Warsaw, Warsaw, Poland)

0478 GENOME PROFILE OF PH POSITIVE ALL IN ADULT PATIENTS
A. Chanalaris, D. Brazma, L. Rai, A. Chanalaris, J. Howard, M. Valgañón,
C. Grace, L. Foroni, E.P. Nacheva (Royal Free & UC Medical School,
London, United Kingdom)

0479 IDENTIFICATION BY OLIGONUCLEOTIDE ARRAYS OF A SUBSET OF T-ALL PATIENTS WITH MYELOID-LIKE GENE PATTERN: POTENTIAL MECHANISMS OF TRANSFORMATION
S. Chiaretti, M. Messina*, S. Tavolaro, V. Fulci, I . Della Starza,
R. Maggio, A.D. Negulici, V. Di Maio, A. Vitale, G. Macino, A. Guarini,
R. Foà (University "Sapienza", Rome, Italy)

0480 ETV6/RUNX1 INTERFERES WITH SPINDLE CHECKPOINT FUNCTION AND TP53 SURVEILLANCE THEREBY PROMOTING TETRAPLOIDIZATION
E. Panzer-Grümayer, A. Inthal, R. Joas, L. Orel, G. Fuka, A. Haas,
G. Krapf (Children's Cancer Research Institute, Vienna, Austria)

0481 CO-ADMINISTRATION OF 2-DEOXY-D-GLUCOSE ALLOWS DEXAMETHASONE DOSAGE REDUCTION IN THE INDUCTION THERAPY OF LYMPHOBLASTIC LEUKEMIA
K. Eberhart, K. Renner, I. Ritter, C. Hellerbrand, B. Timischl, R. Kofler,
P. Oefner (University of Regensburg and Tyrolean Cancer Research
Institute, Regensburg, Germany)

0482 RARE INCIDENCE BUT EXTREME DIVERSITY OF PAX5 FUSION GENES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
K. Nebral, M. König, G. Mann, O.A. Haas, S. Strehl (CCRI, Children's
Cancer Research Institute. St. Anna Kinderkrebsforschung, Wien,
Austria)

0483 NK-LIKE HOMEODOMAIN PROTEINS ACTIVATE TRANSCRIPTION OF POLYCISTRONIC MIR-17-92 AND INHIBIT ETOPOSIDEINDUCED APOPTOSIS IN T-ALL CELLS
S. Nagel, L. Venturini, G.K. Przybylski, P. Grabarczyk, C. Corinna,
H.G. Drexler, C.A. Schmidt, R.A.F. MacLeod, M. Scherr (DSMZ,
Braunschweig, Germany)

0484 CHARACTERIZATION OF NUP214-ABL1 POSITIVE T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REVEALS GENOMIC HETEROGENEITY OF THE FUSION GENE PRESENTATION
C. Graux, N. Dastugue, M. Lafage, F. Mugneret, S. Struski, M.J. Grégoire,
N. Nadal, E. Lippert, M. Stevens-Kroef, P. Vandenberghe, L. Michaux,
A. Bosly, I. Wlodarska, I. Lahortiga, K. De Keersmaecker, J. Cools,
A. Hagemeijer, H.A. Poirel (UCL, Yvoir, Belgium)

0485 ALTERNATIVE SPLICING OF IKAROS MRNA IS RESPONSIBLE FOR THE EXPRESSION OF DIFFERENT ABERRANT ISOFORMS IN PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) PATIENTS
A. Lonetti, I. Iacobucci, R. Zuntini, S. Ferrari, D. Cilloni, F. Messa,
E. Ottaviani, F. Arruga, F. Salmi, S. Paolini, C. Papayannidis,
P.P. Piccaluga, P. Giannoulia, S. Soverini, G. Saglio, F. Pane, A. Vitale,
S. Chiaretti, R. Foà, M. Baccarani, G. Martinelli (Department of
Hematology/Oncology “L. and A. Seràgnoli”, Bologna, Italy)

0486 GLUCOCORTICOID-MEDIATED EFFECTS IN LEUKEMIA CELLS: INVOLVEMENT OF MICRORNAS
R. Mitlohner, P. Rhein, R. Ratei, W.D. Ludwig, L. Karawajew
(RRK, Helios Klinikum Berlin, Charité, Berlin, Germany)

0487 IDENTIFICATION OF MULTIPLE NOVEL IGH@ TRANSLOCATIONS IN ADOLESCENT ACUTE LYMPHOBLASTIC LEUKAEMIA
L. Russell, J. Harrison (Newcastle Universtiy, Newcastle Upon Tyne,
United Kingdom)

0488 WHICH TECHNIQUE(S) TO USE WHEN STUDYING MINIMAL RESIDUAL DISEASE AT DAY 35 IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER APPROACH
B.J. de Moerloose, K. Swerts, M. Bakkus, A. Uyttebroeck, N. Boeckx,
A. Van Damme, P. Vandenberghe, B. Verhasselt, J. Philippé, Y. Benoit
(Ghent University Hospital, Ghent, Belgium)

0489 MOLECULAR CHARACTERIZATION OF CHROMOSOMAL ALTERATIONS IN T-CELL NEOPLASMS BY COMBINING OF FT-CGH AND LM-PCR
G.K. Przybylski, K. Dittmann, P. Grabarczyk, S. Gesk, W. Siewert,
R. Siebert, C.A. Schmidt (Institute of Human Genetics, Poznan, Poland)

0490 TAF1-NUP214 IS A NEW RECURRENT FUSION IN A SUBSET (~3%) OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
P. Gorello, L. Elia, R. La Starza, L. Brandimarte, E. Varasano, A. Vitale,
V. Pierini, M. Longinotti, G. Del Poeta, M.F. Martelli, R. Foà, C. Mecucci
(Hematology, IBiT Foundation, University of Perugia, Perugia, Italy)

0491 THE GENERATION OF SENSITIVE, PATIENT SPECIFIC MOLECULAR PROBES IS FEASIBLE IN MOST ADULT ALL PATIENTS AND ALLOWS THE DEFINITION OF A RISK ADAPTED POSTCONSOLIDATION TREATMENT STRATEGY
O. Spinelli, M. Tosi, B. Peruta, T. Intermesoli, E. Oldani, R. Bassan,
A. Rambaldi (Ospedali Riuniti, Bergamo, Italy)

0492 ADDITIONAL GENETIC FEATURES OF NUP214-ABL1 POSITIVE PEDIATRIC T-ALL
M. Pisecker, M. König, R. Ullmann, S. Strehl (CCRI, Vienna, Austria)

0493 T-LYMPHOCYTE LEUKEMIA CELLS MOLT-4: RESISTANT TO TRAIL, BUT VERY SENSITIVE TO IONIZING RADIATION. COULD LOW DOSES OF RADIATION INCREASE SENSITIVITY TO TRAIL?
M. Rezacova (Charles University, Faculty of Medicine in Hradec
Kralove, Hradec Kralove, Czech Republic)

0494 INCREASED RISK OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN BRAZILIAN INDIVIDUALS WITH NAD(P)H:QUINONE OXIDOREDUCTASE 1 (NQO1) AND CYTOCHROME P450 A1 (CYP1A1) GENE DEFECTS
G. Yamaguti, G. Lourenco, V. Silveira, L.G. Tone, L.F. Lopes,
C.S.P. Lima (State University of Campinas, Campinas, Brazil)

0495 DETECTION OF PROTEIN PATTERNS IN PLASMA OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA USING FUNCTIONALIZED MAGNETIC BEADS AND LINEAR MALDI-TOF MASS SPECTROMETRY
N. von Neuhoff, T. Oumeraci, B. Hirsch, M. Kostrzewa, M. Schrappe,
B. Schlegelberger, G. Cario (Hannover Medical School, Hannover,
Germany)

---

ACUTE MYELOID LEUKEMIA - BIOLOGY II

0496 TIME-DOMAIN OPTICAL IMAGING OF AML XENOGRAFTS WITH NEAR-INFRARED CONJUGATED MONOCLONAL ANTIBODIES
E. Mc Cormack, M. Mujic, B.T. Gjertsen (Institute of Medicine, Bergen,
Norway)

0497 COAGULATION ACTIVATION IN ACUTE PROMYELOCYTIC LEUKEMIA TRANSGENIC MICE MODEL HCG-PML-RAR?
M.C.T. Pintao, B.A.A. Santana-Lemos, F.G. Mangolini,
L.L. Figueiredo-Pontes, F.P. Saggioro, C.L.A. Silva, P.S. Scheucher,
G.A.S. Santos, M.S. Baggio, A.B. Garcia, E.M. Rego (Medical School
of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil)

0498 A ONE-MUTATION MATHEMATICAL MODEL CAN EXPLAIN THE AGE INCIDENCE OF AML WITH MUTATED NUCLEOPHOSMIN (NPM1)
A. Liso, F. Castiglione, A. Cappuccio, F. Stracci, R.F. Schlenk, S. Amadori,
C. Thiede, S. Schnittger, P.J.M. Valk, K. Döhner, M.F. Martelli, M. Schaich,
J. Krauter, A. Ganser, M.P. Martelli, B. Löwenberg, T. Haferlach,
G. Ehninger, F. Mandelli, H. Döhner, F. Michor, B. Falini (University of
Foggia, Foggia, Italy)

0499 COMPLEX AMPLIFICATION OF CHROMOSOME 21 MASKING A NOVEL CRYPTIC RUNX1 GENE FUSION IN AN AML CELL LINE (OCI-M2)
S. Chen, B. Schneider, S. Nagel, R. Geffers, H. Quentmeier,
M. Kaufmann, H. Drexler, R. MacLeod (DSMZ—German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany)

0500 VEGF MRNA LEVELS, PROTEIN CONCENTRATION AND MICROVESSEL DENSITY IN AML PATIENTS, AT DIAGNOSIS AND IN REMISSION
A. Avgitidou, E. Ioannidou, A. Tsiga, E. Vlachaki, F. Klonizakis,
St. Dimoudis, M. Diamantidis, S. Haralambidou, I. Venizelos,
I. Klonizakis (Hippokration Hospital, AUTH, Thessaloniki, Greece)

0501 SECONDARY GENETIC ABERRATIONS AND THEIR EFFECT ON PROGNOSIS IN CORE BINDING FACTOR - ACUTE MYELOID LEUKEMIA (CBF-AML)
J. Markova, Z. Trnkova, J. Maaloufova, J. Stary, P. Cetkovsky, J. Schwarz
(Institute of Hematology & Blood Transf., Prague 2, Czech Republic)

0502 “ESCAPE”-MECHANISM IN CHILDHOOD ACUTE MEGAKARYOBLASTIC LEUKEMIAS
O. Hummel, I. Fränzel, K. Reinhardt, D. Reinhardt (Hannover Medical
School, Hannover, Germany)

0503 MOLECULAR CHARACTERIZATION OF THE MLL-SEPT6 FUSION GENE IN ACUTE MYELOID LEUKAEMIA: IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS AND CLONING OF GENOMIC BREAKPOINT JUNCTIONS
N. Cerveira, F. Micci, J. Santos, M. Pinheiro, C. Correia, S. Lisboa,
S. Bizarro, L. Norton, A. Glomstein, A.E. Åsberg, S. Heim, M.R. Teixeira
(Portuguese Oncology Institute, Porto, Portugal)

0504 INHIBITION OF THE PROLIFERATIVE AND ANGIOGENIC ACTIVITY OF FLT3 INTERNAL TANDEM DUPLICATION MUTANTS FROM ACUTE MYELOID LEUKEMIA CELL LINES BY A TYROSINE KINASE INHIBITOR
L.A. Luis Arístides, N. Barbarroja, M.J. Luque, R.M. Carretero, A. Torres,
V. Velasco, Ch. Lopez-pedrera (Hospital Reina Sofía, Córdoba, Spain)

0505 AKT AND PKC ARE POSSIBLE REGULATORS OF TELOMERASE ACTIVITY DURING DIFFERENTIATION OF MYELOID LEUKEMIC CELLS
O. Yamada, K. Ozaki, M. Nakadake, M. Akiyama, K. Kawauchi,
R. Matsuoka (Tokyo Women's Medical University, Tokyo, Japan)

0506 TAP- AND PROTEASOME-DEPENDENT ENDOGENOUS ANTIGEN LOADING OF HLA CLASS II IN AML BLASTS INTRODUCES ‘REVERSE’ CROSS-PRESENTATION AND A PROMISING NEW TARGET FOR GENERATING LEUKEMIA-SPECIFIC CD4+ T CELLS
M.M. van Luijn, M.E. Ressing, E.J. Wiertz, S. Ostrand-Rosenberg,
Y. Souwer, G.J. Ossenkoppele, A.A. Van de Loosdrecht, S.M. Van Ham
(VU Medical Center, Amsterdam, The Netherlands)

0507 DISRUPTION OF TGF-?ETA SIGNALING IN ACUTE PROMYELOCYTIC LEUKEMIA DEPENDS ON NUCLEAR PML FUNCTION
L.L. Figueiredo-Pontes, B.A.A. Santana-Lemos, R.H. Jácomo,
A.S.G. Lima, A.I. Dore, F.U. Ferreira, A.A. Goes, R.A. Panepucci,
D.T. Covas, A.M. Fontes, R.P. Falcao, E.M. Rego (Medical School of
Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil)

0508 POLYMORPHISMS OF THE DNA REPAIR GENE XRCC1 (399) AND XPD (751) CORRELATES WITH RISK OF ACUTE MYELOID LEUKEMIA IN TURKISH POPULATION
A. Ozcan, M. Pehlivan, E. Karaca, C. Ozkinay, F. Ozdemir, S. Pehlivan
(Ege University, Izmir, Turkey)

0509 PROGNOSTIC SIGNIFICANCE OF MOLECULAR MARKERS IN NORMAL KARYOTYPE -AML: A SINGEL CENTER EXPERIENCE
O. Spinelli, M. Tosi, V. Guerini, P. Zanghì, M. Franchi, I. Taboni,
M. Magri, C. Zanotti, T. Intermesoli, E. Oldani, R. Bassan, A. Rambaldi
(Ospedali Riuniti, Bergamo, Italy)

0510 PTK 787/Z222485, A POTENT INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE PHOSPHORYLATION, MIGHT CONSTITUTE A NEW EFFECTIVE THERAPY TO ACUTE MYELOID LEUKEMIA
N. Barbarroja, L.A. Torres, M.J. Luque, R.M. Carretero, A. Torres,
F. Francisco, Ch. López-Pedrera (Hospital Reina Sofia, Córdoba, Spain)

0511 CHOLESTEROL-RICH DOMAINS REGULATE FLT-1 ACTIVATION SIGNALS IN ACUTE MIELOID LEULKEMIA CELLS
C. Casalou, J.F. Moura Nunes, S. Dias (Portuguese Institut of
Oncology, Lisbon, Portugal)

0512 VASCULAR ENDOTHELIAL GROWTH FACTOR PLAYS AN IMPORTANT ROLE FOR THE RECOVERY OF NORMAL HEMATOPOIESIS AFTER CHEMOTHERAPY IN ACUTE MYELOGENOUS LEUKEMIA CASES
H. Haruko, M. Noguchi, R. Shirasaki, T. Sugao, Y. Oka, K. Kawasugi,
Y. Akiyama, N. Shirafuji (Teikyo University School of Medicine, Tokyo,
Japan)

0513 PROTEOMIC MODIFICATIONS INDUCED BY VALPROIC ACID IN AML1/ETO POSITIVE LEUKEMIA CELLS
V. Santini, F. Buchi, G. Ferrari, E. Spinelli, A. Gozzini, T. Lunghi, A. Bosi
(University of Florence, Firenze, Italy)

0514 PROTEOMIC MODIFICATIONS INDUCED BY AZACITIDINE IN AML1/ETO POSITIVE LEUKEMIA CELLS
V. Santini, F. Buchi, G. Ferrari, E. Spinelli, T. Lunghi, A. Gozzini, A. Bosi
(University of Florence, Firenze, Italy)

---

ACUTE MYELOID LEUKEMIA - CLINICAL II

0515 SAFETY AND EFFICACY EXPERIENCE OF SNS-595 IN RELAPSED/REFRACTORY ACUTE LEUKEMIA PATIENTS = 60 YEARS OLD COMPARED TO <60 YEARS OLD: RESULTS OF A PHASE 1 STUDY
C Michelson, J. Lancet, H. Kantarjian, F. Ravandi, F. Giles, G. Michelson,
J. Karp (Sunesis Pharmaceuticals Inc, South San Francisco, USA)

0516 EXTRA-MEDULLARY MYELOID TUMOR: A RETROSPECTIVE CLINICOPATHOLOGICAL STUDY OF 32 CASES
T. Todd, M. Besser, J. Craig, R. Marcus (Cambridge University
Hospitals NHS Foundation Trust, Cambridge, United Kingdom)

0517 SEQUENTIAL TREATMENT WITH LOW DOSES OF RETINOIC ACID (LOATRA)+/-VALPROIC ACID(VPA) FOLLOWED BY LOW DOSES ARAC(LODAC) IN ELDERLY ACUTE MYELOID LEUKAEMIA(AML)PRELIMINARY CLINICAL AND BIOLOGICAL RESULTS
S. Fenu, C. Nobile, C. Nervi, A. Chierichini, P. Anticoli-Borza,
B. Anaclerico, V. Bongarzoni, R. Bruno, S. Cortese, P. Iacovino,
F. Pauselli, C. Tozzi, G. Cimino, L. Annino (AZ. Osp. S.Giovanni-
Addolorata, Rome, Italy)

0518 IN VITRO CHEMOSENSITIVITY OF “NON LEUKEMIC” CFU-GM, IN AML PATIENTS, IS CORRELATED WITH CD34+ MOBILIZATION AND MAY IDENTIFY GROUPS WITH DIFFERENT DISEASE FREE SURVIVAL
G.S. Sortino, G.M. Milone, G.A. Avola, G.L. Leotta, A.S. Strano,
M.G. Camuglia, M. Poidomani, S. Coppoletta, A. Triolo, S. Toscano,
M.P. Azzaro (Hematology, Catania, Italy)

0519 LEUKEMIA-FREE SURVIVAL (LFS) AS A SURROGATE FOR OVERALL SURVIVAL (OS) IN AML PATIENTS IN REMISSION (CR):A TRIAL OF A NOVEL IMMUNOTHERAPY WITH HISTAMINE DIHYDROCHLORIDE PLUS LOW-DOSE IL-2 (HDC/IL-2)
M.E. Buyse, P. Squifflet, S.E. Allard, D. Bhagwat, J.M. Rowe (International
Drug Development Institute (IDDI), Louvain-la-neuve, Belgium)

0520 5-AZACYTINE IMPROVES SURVIVAL IN RELAPSED/REFRACTORY AML, RESULTS OF A MONOCENTRIC ANALYSIS OF 21 CASES
S. Ayari, T. Guillaume, P. Chevallier, E. Brissot, T. Gastinne, M. Mothy,
.J.L Harousseau, J.D. Delaunay (University Hospital, Nantes, France)

0521 THE INCIDENCE AND SURVIVAL OF ACUTE DE NOVO LEUKEMIAS IN ESTONIA AND IN A WELL-DEFINED REGION OF WESTERN SWEDEN DURING 1997-2001: A SURVEY OF PATIENTS AGED 16-64 YEARS
L. Wennstrom, E. Holmberg, D. Stockelberg, S. Safai-Kutti, K. Vaht,
E. Luik, H. Everaus, K. Palk, M. Varik, I. Viigimaa, J. Kutti (Sahlgrenska
University Hospital, Göteborg, Sweden)

0522 COMPLEX REARRANGEMENTS RESULTING IN LOSS OF BOTH 20Q AND 17P IN AML
J. Julie, J.D. Howard, M. Valgañón, C. Grace, H. Mazzulo, M. Griffith,
P. Nacheva (Royal Free & UC Medical School, London,
United Kingdom)

0523 A PHASE I STUDY OF TIPIFARNIB AND BORTEZOMIB IN THE TREATMENT OF POOR RISK ADULT ACUTE MYELOID LEUKEMIA
S. Paolini, E. Ottaviani, B. Lama, F. De Rosa, C. Laterza, P. Giannoulia,
I. Iacobucci, C. Papayannidis, S. Parisi, P.P. Piccaluga, F. Salmi,
M. Baccarani, G. Martinelli (Istituto di Ematologia e Oncologia Medica
"L. e A. Seràgnoli, Bologna, Italy)

0524 INCIDENCE AND CHARACTERISTICS OF CD56+ ACUTE MYELOID LEUKEMIA IN ADULTS AND CHILDREN: CD56 EXPRESSION IS HIGHER INCIDENCE AND STRONG ASSOCIATION WITH CNS INVOLVEMENT IN CHILDHOOD ACUTE MYELOID LEUKEMIA
H.R. Lee, I.H. Kim, S.S. Yoon, S.Y. Park, B.K. Kim, H.J. Kang,
H.Y. Shin, H.S. Ahn, H.K. Kim, M.H. Park, H.I. Cho, D.S. Lee (Seoul
National University College of Medicine, Seoul, South-Korea)

0525 MOLECULAR MONITORING OF BAALC AS A MINIMAL RESIDUAL DISEASE MARKER IN PATIENTS WITH NEWLY DIAGNOSED ACUTE LEUKEMIA
Y. Najima, K. Ohashi, T. Yamashita, H. Akiyama, H. Sakamaki (Tokyo
Metropolitan Komagome Hospital, Tokyo, Japan)

0526 LOW DOSE GENTUZUMAB OZOGAMICIN, AFTER INTENSIVE INDUCTION IN OLDER AML PATIENTS: RESULTS IN 13 PATIENTS IN A SINGLE CENTRE INSTITUTION
A. Poloni, S. Trappolini, B. Costantini, D. Capelli, E. Troiani, G. Mancini,
G. Discepoli, M. Montanari, G. Gini, I. Scortechini, P. Leoni, A. Olivieri
(Clinica di Ematologia, Ancona, Italy)

---

CHRONIC LYMPHOCYTIC LEUKEMIA - PROGNOSTIC FACTORS

0527 HIGH CD54 CELL SURFACE EXPRESSION ON B CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME
P. Bulian, M.I. Del Principe, A. Zucchetto, L. Maurillo, R. Bomben,
F. Buccisano, M. Dal Bo, F. Luciano, F.M. Rossi, A. Venditti, M. Degan,
S. Amadori, V. Gattei, G. Del Poeta (IRCCS CRO, Aviano, Italy)

0528 MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
M. Mraz, J. Kotaskova, B. Tichy, K. Malinova, M. Trbusek,
Y. Brychtova, J. Mayer, S. Pospisilova (Medical Faculty MU and
University Hospital Brno, Brno, Czech Republic)

0529 INFERIOR OVERALL SURVIVAL IN CLL PATIENTS WITH TP53 MUTATIONS AND MDM2 SNP309 POLYMORPHISM
R.H. Linderholm, K. Willander, K. Karlsson, P. Söderkvist
(Linköping University Hospital, Linköping, Sweden)

0530 GENE EXPRESSION PROFILE OF CLL PATIENTS TREATED WITH DNA-DAMAGING AGENTS IDENTIFIES BIOLOGICAL PATHWAYS IMPLICATED IN RESPONSE ACHIEVEMENT AND RELAPSE
N. Villamor, F. Bosch, A. Ferrer, M. Aymerich, A. Muntañola, P. Jares,
D. Colomer, E. Montserrat, E. Campo (Hospital Clínic, Barcelona, Spain)

0531 CLL PATIENT COMPARISON ACCORDING TO ZAP70 MRNA LEVEL : NEW PROGNOSTIC FACTORS, DIFFERENCES IN MICRORNA EXPRESSION AND DISTINCT INTERACTION CAPACITIES WITH THE MICROENVIRONMENT
B. Stamatopoulos, H.B. Haibe-Kains, N. Meuleman, D. Bron,
P. Martiat, L. Lagneaux (Bordet Institute, Brussels, Belgium)

0532 QUANTITATIVE GENE EXPRESSION ANALYSES OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL
D. Kienle, A. Benner, C. Läufle, D. Winkler, A. Bühler, A. Habermann,
T. Zenz, R. Dalla-Favera, P. Lichter, H. Döhner, S. Stilgenbauer
(University of Ulm, Ulm, Germany)

0533 A DISTINCTIVE TRASCRIPTIONAL PROFILE CHARACTERIZES THE CHROMOSOME 17P LOSS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
S. Fabris, L. Mosca, K. Todoerti, G. Cutrona, S.. Matis, M. Colombo,
L. Agnelli, M. Lionetti, D. Intini, M. Gentile, M. Mauro, V. Callea, G. Festini,
S. Molica, G. Lambertenghi-Deliliers, F. Morabito, M. Ferrarini, A. Neri
(Università di Milano, Fondazione IRCCS Policlinico, Milano, Italy)

0534 INTEGRATIVE GENOMIC ANALYSIS OF TRISOMY 12 ABNORMALITY IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
L. Mosca, K. Todoerti, S. Fabris, G. Cutrona, S. Matis, M. Colombo,
L. Agnelli, M. Lionetti, M. Gentile, M. Spriano, V. Callea, G. Festini,
S. Molica, G. Lambertenghi-Deliliers, F. Morabito, M. Ferrarini, A. Neri
(Università di Milano, Fondazione IRCCS Policlinico, Milano, Italy)

0535 ANALYSIS OF TP53 MUTATION IN A LARGE COHORT OF CLL PATIENTS BEFORE FIRST-LINE TREATMENT: ANALYSIS OF THE GENETIC PROFILE WITHIN THE CLL4 TRIAL (F VS. GCLLSG
T. Zenz, T. Denzel, S. Häbe, D. Winkler, A. Bühler, R. Busch, B. Eichhorst,
M. Hallek, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0536 SCREENING FOR COPY-NUMBER ALTERATIONS AND LOSS-OFHETEROZYGOSITY IN CHRONIC LYMPHOCYTIC LEUKEMIA - A COMPARATIVE STUDY OF FOUR DIFFERENTLY DESIGNED, HIGH RESOLUTION MICROARRAY PLATFORMS
R. Gunnarsson, J. Staaf, M. Jansson, A.M. Ottesen, H. Göransson,
U. Liljedahl, U. Ralfkiær, M. Mansouri, A.M. Buhl, K. Ekström Smedby,
H. Hjalgrim, A.C. Syvänen, Å. Borg, A. Isaksson, J. Jurlander, G.
Juliusson, R. Rosenquist (Lund University, Lund, Sweden)

0537 CYTOGENETIC ABNORMALITIES DEL(17P) AND DEL(11Q) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE STUDY ON 156 YOUNG PATIENTS IN DIFFERENT PHASES OF THE DISEASE
I. Del Giudice, F.R. Mauro, M. Nanni, M.S. De Propris, S. Santangelo,
M. Marinelli, N. Peragine, F. Mancini, D. Armiento, L. Quattrocchi,
A. Guarini, R. Foa' (University "La Sapienza", Rome, Italy)

0538 SPONTANEOUS CLINICAL REMISSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 9 CASES
I. Del Giudice, F.R. Mauro, S. Chiaretti, S. Tavolaro, S. Santangelo,
M. Marinelli, R. Maggio, M.S. De Propris, F. Mancini, L. Quattrocchi,
D. Armiento, A. Guarini, R. Foa' (University "La Sapienza", Rome, Italy)

0539 P53 EVALUATION IN CLL BY P53 ARRAY: A SIMPLE, SENSITIVE AND SPECIFIC METHOD THAT UNRAVELS A HIGH PERCENTAGE OF POLYMORPHISMS AND MUTATIONS
S. Chiaretti, S. Tavolaro, M. Messina*, M. Marinelli, I. Del Giudice,
F.R. Mauro, S. Santangelo, N. Peragine, S. Truong, M.S. De Propris,
M. Nanni, A. Guarini, R. Foà (University "Sapienza", Rome, Italy)

0540 PRESENCE OF HETEROZYGOUS ATM DELETION MAY NOT BE CRITICAL FOR THE RESPONSE OF CLL CELLS TO FLUDARABINE
M. Trbusek, S. Cejkova, L. Rocnova, D. Potesil, J. Smardova,
J. Malcikova, D. Zezulkova, M. Doubek, Y. Brychtova, S. Pospisilova,
J. Mayer (University Hospital Brno, Brno, Czech Republic)

0541 CYTOTOXIC EFFECT OF SDX-308, ANALOGUE OF R-ENANTIOMER OF ETODOLAC, IN COMBINATION WITH PURINE ANALOGUES OR MONOCLONAL ANTIBODIES ON EX VIVO B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
P. Robak, T. Robak, P. Smolewski, A. Linke, B. Cebula (Medical
University of Lodz, Lodz, Poland)

---

CHRONIC MYELOID LEUKEMIA - CLINICAL II

0542 THE VARIANCE IN PATIENT-REPORTED NONADHERENCE WITH IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA IS ATTRIBUTABLE TO BOTH PHYSICIANS AND PATIENTS - RESULTS FROM THE ADAGIO STUDY
L. Abraham, L. Noens, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman,
Ph. Martiat, Ph. Mineur, K. Van Eygen, M.-A. Van Lierde, K. MacDonald,
S. De Geest, T. Albrecht, I. Abraham (Matrix45, Earlysville, USA)

0543 IMATINIB PLASMA LEVELS CORRELATE WITH MOLECULAR RESPONSE IN CML PATIENTS
E. Faber, D. Friedecky, J. Tomkova, S. Rozmanova, P. Rohon,
I. Skoumalova, T. Adam, M. Jarosova, K. Indrak (University Hospital,
Olomouc, Czech Republic)

0544 ANALYSIS OF BCR-ABL MUTATIONS IN MEXICAN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PHILADELPHIACHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) TREATED WITH NILOTINIB
J.L. Ayala, R. Hurtado, N. Delgado, P. Vargas, L. Meillon, N. Tapia,
M. Alvarado, J. De Diego, P. Azaola, M. Gonzalez, Y. Lugo, R. Hernandez,
J.J. Kassack, S. Cleto, M. Nambo, G. Reyes, O. Cantu, A. Aguayo,
I. Mucius, A. Herrera, K. Nacho (Instituto Mexicano del Seguro Social,
Mexico City, Mexico)

0545 MANAGEMENT OF CHRONIC MYELOID LEUKAEMIA IN CLINICAL PRACTICE IN FRANCE: RESULTS OF THE FRENCH COHORT OF THE UNMET NEEDS IN CML (UNIC) STUDY
M. Michallet, F. Maloisel, C. Chaleteix, M. Hacini, F. Huguet, A. Oukessou,
B. Bregman, A. Guerci (Hôpital Edouard Herriot, Lyon, France)

0546 MULTICENTER OPEN LABEL STUDY OF SUBCUTANEOUS (SC) OMACETAXINE (OMA) IN CHRONIC MYELOID LEUKEMIA (CML)PATIENTS (PTS) THAT ARE RESISTANT OR INTOLERANT TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
J. Cortes, M. Wetzler, L. Akard, J.H. Lipton, A.C. Benichou, A.R. Craig,
E. Humphriss, H. Kantarjian (MD Anderson Cancer Center, Houston, USA)

0547 LONG-TERM SURVIVAL IN CHRONIC MYELOCYTIC LEUKEMIA AFTER A FIRST PRIMARY MALIGNANCY
D. Pulte, A. Gondos, H. Brenner (Weill Cornell Medical College,
New York, USA)

0548 SEQUENTIAL MOLECULAR MONITORING OF PATIENTS WITH CHRONIC PHASE MYELOGENOUS LEUKEMIA DURING IMATINIBMESYLATE TREATMENT. CLINICAL SIGNIFICANCE AND PREDICTIVE VALUE
H Kamel, Y El-Nahas, M Abdel Moaty, R Abdel Fattah, M El Emary,
W. ElMetnawy (National Cancer Institute, Cairo University, Cairo, Egypt)

0549 MULTICENTER EXPERIENCE WITH IMATINIB MESYLATE IN 202 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
A.M. Carella, E. Orlandi, M. Lazzarino, M. Annunziata, F. Ferrara,
E. Pungolino, E. Morra, C. Baratè, M. Petrini, M. Miglino, M. Gobbi
(Hematology Division, Genoa, Italy)

0550 NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
M.K.M. Koren-Michowitz, P. Le Coutre, J. Duyster, C. Scheid,
J.M. Rowe, N. Goldschmidt, E. Ribakovsky, A. Nagler (Chaim Sheba
Medical Center, Ramat Gan, Israel)

0551 NONADHERENCE WITH IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA IS A FUNCTION OF DISEASE, HEALTH, KNOWLEDGE, AND SOCIAL FACTORS - RESULTS FROM THE ADAGIO STUDY
L. Abraham, L. Noens, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman,
Ph. Martiat, Ph. Mineur, K. Van Eygen, M.-A. Van Lierde, K. MacDonald,
S. De Geest, T. Albrecht, I. Abraham (Matrix45, Earlysville, USA)

0552 FLOW CYTOMETRIC ANALYSIS OF ONCOGENIC SIGNAL TRANSDUCTION PATHWAYS IN PRIMARY LEUKAEMIC CELLS
A. Beel, B. Wasag, V. Van Duppen, J. Cools, D. Bron, L. Michaux,
G. Verhoef, P. Vandenberghe (KULeuven, Leuven, Belgium)

0553 COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND IMATINIB FOR CHRONIC MYELOID LEUKEMIA: RESULTS FROM CAMELIA REGISTRY
E. Faber, J. Muzik, V. Koza, E. Demeckova, J. Voglova, L. Demitrovicova,
J. Chudej, I. Markuljak, E. Cmunt, T. Kozak, E. Tothova, M. Jarosova,
L. Dusek, K. Indrak (University Hospital, Olomouc, Czech Republic)

0554 IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
J. Mayer, H. Klamova, D. Zackova, M. Doubek, P. Cetkovsky,
J. Rulcova, K. Machova, J. Moravcova, D. Dvorakova, T. Jurcek
(University Hospital, Brno, Czech Republic)

0555 THERE ARE NOT ONLY POINT MUTATIONS BUT ALSO SPLICING DEFECTS IN BCR-ABL GENE IN CML PATIENTS TREATED BY IMATINIB
A.V. Misyurin, M.V. Suchkova, A.A. Krutov, E.V. Aksenova,
V.V. Tikhonova, A.G. Turkina, N.D. Khoroshko (National Research
Center for Hematology, Moscow, Russian Federation)

0556 HAS SIMULTANEOUS PREGNANCY NEGATIVELY INFLUENCED PROGRESSION AND TREATMENT RESPONSE IN CML?
H. Klamova, J. Moravcova, K. Machova, J. Brezinova, M. Markova
(Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

0557 THE OCCURRENCE OF PLEURAL/PERICARDIAL EFFUSIONS IN PH+ CML PATIENTS FAILING PRIOR TYROSINE KINASE INHIBITORS (TKI) BEFORE STARTING NILOTINIB – ANALYSIS OF DATA FROM COMPASSIONATE USE PROGRAM
P. le Coutre, E. ODwyer, L. Mendes, C. Woodman (Charité, Berlin,
Germany)

0558 USEFULNESS OF IN VITRO SENSITIVITY TESTING OF LEUKEMIC CELLS TO KINASE INHIBITORS FOR THE MANAGEMENT OF TREATMENT WITH IMATINIB AND DASATINIB IN CML PATIENTS
R. Solna, J. Veselovska, S. Rozmanova, E. Faber, M. Jarosova,
M. Holzerova, K. Indrak, V. Divoky (Department of Biology, Faculty of
Medicine, Palacky University, Olomouc, Czech Republic)

0559 DASATINIB PHARMACOKINETICS AND EXPOSURE–RESPONSE (E–R): RELATIONSHIPS TO EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP)
C. Nicaise, X. Wang, A. Roy, M. Pfister, T.T. Chen, E. Bleickardt,
A. Hochhaus, N.P. Shah, F.E. Nicolini, R.E. Clark, G. Saglio,
H. Kantarjian (Bristol-Myers Squibb, Wallingford, Connecticut, USA)

---

CYTOGENETICS AND MOLECULAR DIAGNOSTICS II

0560 A NOVEL MGB PROBE-BASED ASSESSMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CARRYING NPM1 (NUCLEOPHOSMIN) EXON 12 MUTATIONS
D. Dvorakova, D. Ohlidalova, J. Pospisilova, M. Lengerova, J. Mayer
(University Hospital Brno, Brno, Czech Republic)

0561 THE POOR PROGNOSIS ASSOCIATED WITH GAIN/AMPLIFICATION OF 1Q21 IN RELAPSED MULTIPLE MYELOMA PATIENTS MAY BE OVERCOME BY VELCADE BASED REGIMEN IN CONTRARY OF THALIDOMIDE BASED REGIMEN
P. Nemec, H. Greslikova, J. Smetana, R. Zaoralova, R. Kupska,
K. Berankova, H. Filkova, D. Kralova, M. Krejci, L. Pour, L. Zahradova,
V. Sandecka, Z. Adam, P. Kuglik, R. Hajek (University Research Centre
- Czech Myeloma Group, Brno, Czech Republic)

0562 HOMOZYGOUS DELETION OF P16, P14 AND P15 IS A

POOR PROGNOSTIC FACTOR IN ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA, NOT IN CHILDHOOD B-ALL: A COMPARISON THROUGH DELETION AND HYPERMETHYLATION STUDY
M. Kim, S.H. Yim, N.S. Cho, S.H. Kang, H.Y. Kim, B. Oh, T.Y. Kim,
H.J. Min, C.J. She, H.S. Ahn, S.S. Yoon, H.R. Shin, H.I. Cho, D.S. Lee
(Seoul National University Hospital, Seoul, South-Korea)

0563 CHROMOSOMAL INSTABILITY IS CORRELATED WITH PROGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Ch.E. Heilig, H. Löffler, A. Jauch, U, Mahlknecht, A.D. Ho, A. Krämer
(Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany)

0564 AN ANALYSIS OF FMS-LIKE TYROSINE KINASE IN CHILDHOOD ACUTE LEUKAEMIAS
A.S. Leow, H. Ariffin, S.K.Y. Kham, T.C. Quah, A.E.J. Yeoh (National
University of Singapore, Singapore, Singapore)

0565 GAINS OF CHROMOSOME 1Q IN PATIENTS IN RELAPSE AND PROGRESSION OF MULTIPLE MYELOMA
J. Balcarkova, H. Urbankova, V. Scudla, M. Holzerova, J. Bacovky,
M. Zemanova, K. Indrak, M. Jarosova (University Hospital Olomouc,
Olomouc, Czech Republic)

0566 FLT3-ITD, NPM1 MUTATIONS AND WT1 HYPEREXPRESSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
E. Such, J. Cervera, A. Valencia, O. Fuster, M.L. Senent, I. Luna,
E. Marco, M. Mallo, F. Solé, E. Barragán, R. Collado, A. Vicente,
V. Amigo, J.C. Hernández-Boluda, E. Luño, S. Oltra, P. Bolufer,
M.A. Sanz, G. Sanz (Hospital Universitario La Fe, Valencia, Spain)

0567 MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN CML PATIENTS: COMPARISON BETWEEN AUTOMATED FISH ANALYSIS AND RQ-PCR
G. Calabrese, D. Fantasia, F. Pompetti, R. Di Gianfilippo,
P. Guanciali-Franchi, D. Romagno, E. Morizio, M. Alfonsi, S. Pulini,
A. Spadano, R. Di Lorenzo, P. Di Bartolomeo, A. Iacone, G. Palka
(University of Chieti, Chieti Scalo, Italy)

0568 ANALYSIS OF FLT3-ITD IN 147 PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
L. ZAMORA, M. Cabezón, J. Grau, J. Ayats, M. Morgades, S. Marcé,
B. Patiño, D. Dominguez, I. Granada, N. Ruiz-Xivillé, M. Xandri,
A. Cisneros, A. Serrano, N. Lloveras, J. Juncà, A. Oriol, M. Arnan,
C. Boqué, R.F. Duarte, A. Fernández de Sevilla, J.M. Ribera, F. Millá,
E. Feliu (Hospital Germans Trias I Pujol - ICO, Badalona, Spain)

0569 MOLECULAR CYTOGENETIC STUDY OF CHILDHOOD T-ALL
L. Babicka, E. Malinova, Z. Zemanova, A. Berkova, J. Tajtova, J. Zuna,
E. Mejstrikova, J. Stary, K. Michalova (General Faculty Hospital and
1st Faculty of Medicine, Charles University, Prague, Czech Republic)

0570 MIRNA PROFILING MAY BE APPLIED TO THE DIAGNOSIS OF ACUTE LEUKEMIAS
I. Sánchez-Ortega, M. Carricondo, A. Lasa, E. Bussaglia, C. Canals,
A. Aventín, J. Sierra, J.. Nomdedéu (Hospital de la Santa Creu i Sant
Pau, Barcelona, Spain)

0571 HIGH FREQUENCY OF RUNX1 MUTATIONS IN DE NOVO ACUTE MYELOID LEUKEMIA WITH PARTIAL TANDEM DUPLICATION OF MLL
D.C. Liang, L.Y. Shih, C.F. Huang, T.L. Lin, Y.S. Shih, M.C. Kuo,
T.H. Lin, C.L. Lai (Mackay Memorial Hospital, Taipei, Taiwan)

0572 HIGH EXPRESSION OF ETS-RELATED GENE, ERG, PREDICTS POORER OUTCOME IN AML INTERMEDIATE RISK PATIENTS WITH ABNORMAL KARYOTYPE
V. Kairisto, M. Hämäläinen, V. Juvonen, T. Lakkala, J. Johansson,
T.-T. Pelliniemi, T.T. Salmi, K. Remes (Tykslab, Turku, Finland)

---

EPIGENETICS, TRANSCRIPTION AND SIGNALLING

0573 IN VITRO AND IN VIVO STUDY OF TREATMENT WITH THE HDAC INHIBITOR VALPROIC ACID (VPA) IN TWO PATIENTS AFFECTED BY ACUTE MYELOID LEUKAEMIA POST MYELODYSPLASTIC SYNDROME
C. Tatarelli, M.A. Aloe Spiriti, F. Saltarelli, E. Conte, E. Montefusco,
G. La Verde, A. Ferrari, B. Monarca, C. Nervi (Azienda Ospedaliera
Sant'Andrea, Rome, Italy)

0574 IDENTIFICATION OF NOVEL EPIGENETICALLY SILENCED TUMOUR SUPPRESSOR GENES IN HODGKIN AND NON-HODGKIN LYMPHOMA
S. Röhrs, J. Romani, A. Rosenwald, W. Dirks, H.G. Drexler, H. Quentmeier
(DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen,
Braunschweig, Germany)

0575 EPIGENETIC REGULATION OF WNT PATHWAY BY ABERRANT HYPERMETHYLATION OF WNT ANTAGONISTS IN ACUTE MYELOID LEUKEMIA (AML)
A. Valencia, J. Román-Gomez, J. Cervera, E. Such, E. Marco,
E. Barragan, P. Bolufer, M.L. Senent, F. Moscardo, M.A. Sanz (Hospital
Universitario La Fe, Valencia, Spain)

0576 EPIGENETIC CONTROL OF MHC2TA TRANSCRIPTION IN HUMAN T CELL ACTIVATION AND IN T LEUKEMIA CELLS
P.J. van den Elsen, M.C.J.A. Van Eggermond, D.R. Boom, T.M. Holling
(Leiden University Medical Center, Leiden, Netherlands)

0577 MICRORNA IMPLICATION IN EVI1 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA
M. Gomez-Benito, I. Vazquez, C. Vicente, A. Conchillo, N. Marcotegui,
E. Bandres, M.D. Odero (CIMA, University of Navarra, Pamplona, Spain)

0578 THE SECOND SIGNAL IN ANTIGEN-PRESENTING CELLS: COMPLEMENTARY JAK/STAT AND CD40 SIGNALLING MEDIATE PRO-INFLAMMATORY ACTIVATION
T. Luft, M. Conzelmann, E. Rodionova, M. Hess, A. Zota, T. Giese,
S. Breit, P. Dreger, T. Luft (University of Heidelberg, Heidelberg, Germany)

0579 JAK KINASE- AND LYSINE-CONTROLLED TRAFFICKING OF G-CSF RECEPTOR (CSF3R) ARE INDEPENDENT MECHANISMS AND SIMULTANEOUS PERTURBATION OF THESE PATHWAYS RESULTS IN G-CSF INDEPENDENT SIGNALING
J.C.M. Meenhuis, M. Irandoust, M. Valkhof, I.P. Touw (Erasmus MC,
Rotterdam, The Netherlands)

0580 TOLL-LIKE RECEPTOR 4 ACTIVATION IN THE BONE MARROW OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA MAY CONTRIBUTE TO THE INFLAMMATORY MARROW ENVIRONMENT
M. Velegraki, N. Kanellias, I. Mavroudi, G. Eliopoulos, H. Papadaki
(University of Crete School of Medicine, Heraklion, Crete, Greece)

0581 THE ONCOGENIC C-KIT/D816V MUTANT CIRCUMVENTS THE REQUIREMENT OF SRC FAMILY KINASES FOR C-KIT SIGNAL TRANSDUCTION
E. Pedersen, J. Sun, L. Ronnstrand (Laboratory Medicine, Malmö,
Sweden)

0582 G-CSF INDUCES A SPECIFIC TOLEROGENEIC T CELL SUBSET IN

THE HUMAN SYSTEM
A. Franzke, S.N. Ukena, S. Lauszus, J. Grosse, R. Geffers, A. Ganser
(Hannover Medical School, Hannover, Germany)

0583 THE GLYCOGENSYNTHASE KINASE 3ß IS CRITICALLY INVOLVED IN THE APOPTOTIC RESPONSE IN HEMATOPOIETIC CELLS
J. Basecke, S. Horn, A. Lehmann, U. Bergholz, J.A. McCubrey,
L. Trümper, C. Stocking, J. Basecke (University of Goettingen,
Goettingen, Germany)

0584 DISTRIBUTION AND FUNCTION OF CD40/CD40L IN THE BONE MARROW GRANULOCYTIC PROGENITOR AND PRECURSOR CELLS. POSSIBLE PATHOPHYSIOLOGIC SIGNIFICANCE
I. Mavroudi, V. Papadaki, M. Velegraki, A. Eliopoulos, H. Papadaki
(University of Crete School of Medicine, Heraklion, Crete, Greece)

0585 HEMATOPOIETIC STEM CELLS MOBILIZATION BY G-CSF OR LTB4 WAS SIGNIFICANTLY SUPPRESSED BY AN OXYGEN RADICAL SCAVENGER OR AN INHIBITOR OF NADPH OXIDASE
Y.C. Mun, S.A. Oh, K.E. Lee, E.S. Yoo, M.Y. Choi, J.Y. Ahn, J.H. Kim,
C.M. Seong (Ewha Womans University Hospital, Seoul, South-Korea)

0586 BENDAMUSTINE (TREANDA) CYTOTOXICITY IN B-CELL NEOPLASMS REQUIRES PRODUCTION OF REACTIVE OXYGEN SPECIES AND CASPASE-UNRELATED PROCESS IRRESPECTIVE OF P53 STATUS
G. Roue, M. López-Guerra, P. Milpied, P. Pérez-Galán, N. Villamor,
E. Montserrat, E. Campo, D. Colomer (Hospital Clinic - Hematopathology
Unit, Barcelona, Spain)

0587 AURORA KINASE-A AND -B INHIBITION ENHANCE THE CHEMOTHERAPY-INDUCED CELL DEATH IN MYELOID LEUKEMIA CELLS THROUGH CASPASE-DEPENDENT PATHWAY OR MITOTIC CATASTROPHE ACCORDING TO CHEMOTHERAPEUTIC AGENTS
J.-W. Cheong, J.I. Eom, H.I. Jung, H.K. Jeung, J.S. Kim, Y.H. Min
(Yonsei University College of Medicine, Seoul, South-Korea)

0588 CYCLIN D1 DE NOVO EXPRESSION IN B LYMPHOCYTES MEDIATES RESISTANCE TOWARDS APOPTOSIS THROUGH UP-REGULATION OF MOLECULAR CHAPERONES AND REDISTRIBUTION OF CELL DEATH REGULATORS
G. Roue, V. Pichereau, H. Lincet, D. Colomer, B. Sola (Hospital Clinic -
Hematopathology Unit, Barcelona, Spain)

0589 INHIBITION OF BOTH PROTEIN KINASE CK2A AND PI3K/AKT

SYNERGISTICALLY INDUCES APOPTOSIS OF CD34+CD38-LEUKEMIA STEM CELLS WHILE SPARING NORMAL HEMATOPOIETIC STEM CELLS THROUGH INHIBITION OF MULTIPLE DEREGULATED SIGNALING PATHWAYS
J.-W. Cheong, Y.H. Min, J.I. Eom, H.Y. Choi, S.H. Yoon, J.S. Kim
(Yonsei University College of Medicine, Seoul, South-Korea)

---

GENE THERAPY AND CELLULAR IMMUNOTHERAPY AND VACCINATION

0590 INDUCTION OF GAMMA-GLOBIN EXPRESSION AND FETAL HEMOGLOBIN PRODUCTION AFTER EPISOMAL GENE TRANSFER OF A SYNTHETIC ZINC-FINGER ACTIVATOR, IN K562 AND MURINE PROGENITOR CELLS
F.E. Stavrou, E. Lagadinou, E. Papapetrou, N. Zoumbos, C. Barbas,
K. Peterson, A. Athanassiadou (University of Patras, Patras, Greece)

0591 BCR-ABL PEPTIDE VACCINATION DOES NOT INDUCE TOLERANCE IN CML PATIENTS: EVIDENCE FROM THE EPIC TRIAL
J.M. Rojas, K. Knight, L.H. Wang, R.E. Clark (University of Liverpool,
Liverpool, United Kingdom)

0592 VIGOROUS PRIMING OF MINOR HISTOCOMPATIBILITY ANTIGEN SPECIFIC T CELLS BY FREQUENT HIGH DOSE PEPTIDE VACCINATION MAY LEAD TO PROLONGED T CELL RECEPTOR DOWNREGULATION, IMPAIRED T CELL FUNCTIONALITY, AND PROMOTION OF TUMOR ESCAPE
I. Jedema, L. van Dreunen, M.M. van Loenen, M.H.M. Heemskerk,
R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center,
Leiden, The Netherlands)

0593 EX-VIVO GENERATION OF CLINICALLY RELEVANT AMOUNTS OF HUMAN NATURAL KILLER CELLS FOR IMMUNOTHERAPY AGAINST ACUTE MYELOID LEUKEMIA
J. Spanholtz, M. Tordoir, T. De Witte, H. Dolstra (UMCN, Nijmegen, The
Netherlands)

0594 DENDRITIC CELLS (DC) AS PROGNOSTIC INDICATORS OR IMMUNOTHERAPEUTIC TOOLS TO TREAT ACUTE MYELOID LEUKEMIA: ROLE OF THE QUALITY OF LEUKEMIA-DERIVED DC TO PREDICT THE SPECIFIC ANTI-LEUKEMIC POTENTIAL OF (DC-TRAINED) T-CELLS
M. Schmetzer, C. Grabrucker, A. Liepert, A. Kremser, J. Loibl,
M. Freudenreich, R. Reibke, R. Buhmann, T. Yang, C. Schmid, T. Kroell,
H.-J. Kolb (University of Munich, Munich, Germany)

0595 DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AT 7 MONTHS AFTER T CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION REDUCES RELAPSE RISK
W.A. Marijt, A. Borne, von dem, M.Y. Barge, P. Deutz-Terlouw,
M. Beaumont, C.W.J. Starrenburg, E. Fibbe, R. Willemze,
J.H.F. Falkenburg (Leiden University Medical Center, Leiden,
The Netherlands)

0596 DEVELOPMENT OF A LARGE SCALE, NON-VIRAL PLATFORM FOR GENERATION OF REDIRECTED T CELLS FOR ADOPTIVE TRANSFER
E. Rian, H. Almåsbak, A.M. Rasmussen, G. Borelli, M. Lundby,
G. Kvalheim, J. Olweus, M. Pule, C. Rossig, G. Gaudernack (Institute
of Cancer Research, Rikshospitalet University Hospital, Oslo, Norway)

0597 AUTOLOGOUS DENDRITIC CELL VACCINATION IN MULTIPLE MYELOMA PATIENTS – A FIRST CLINICAL RESULTS AND SAFETY EVALUATION IN A PHASE II CLINICAL TRIAL
L.Z. Zahradova, D. Ocadlikova, L. Kovarova, J. Smejkalova, L. Pour,
M. Penka, J. Michalek, R. Hajek (University Hospital, Brno,
Czech Republic)

0598 OXIDIZED MANNAN POTENTIATES DNA VACCINE FOR USE IN CANCER IMMUNOTHERAPY
C.K. Tang, G. Pietersz, V. Apostolopoulos (Burnet Institute,
Melbourne, Australia)

0599 IMMUNE AUGMENTATION OF DENDRITIC CELL VACCINES FOR ACUTE AND CHRONIC LEUKAEMIAS – USE OF MONOCLONAL ANTIBODIES AND LENALIDOMIDE
J. Duncan, H. Roddie (Centre for Regenerative Medicine, Edinburgh,
United Kingdom)

0600 CELL-FREE VACCINATION WITH ACUTE MYELOID LEUKEMIACELL DERIVED EXOSOMES PROLONGS SURVIVAL IN MURINE LEUKEMIA MODEL THROUGH EFFECTIVE INDUCING CYTOTOXIC T-CELL GENERATION
J.-W. Cheong, Y.H. Min, A.J. Choi, H.K. Jeung, H.Y. Choi, S.J. Kim,
J.S. Kim (Yonsei University College of Medicine, Seoul, South-Korea)

0601 ATTENUATED DOSES OF RITUXIMAB FOR THE TREATMENT OF ADULTS WITH AUTOIMMUNE CYTOPENIAS
G. D'Arena, P.R. Scalzulli, M. Nobile, A. La Sala, C. Bodenizza,
M. Dell'Olio, S. Mantuano, G. Rossi, N. Cascavilla ("Casa Sollievo della
Sofferenza" Hospital, San Giovanni Rotondo, Italy)

0602 SELECTIVE DEPLETION OF ALLOREACTIVE DONOR T LYMPHOCYTES AND STUDY OF ANTI-TUMOR ACTIVITY OF SPECIFIC T CELL CLONES IN PATIENS WITH LEUKEMIA AND MULTIPLE MYELOMA
E. Matejkova, D. Ocadlikova, J. Muzikova, P. Vidlakova, D. Kyjovska,
E.S. Vitetta, R. Hajek, J. Michalek (Masaryk University, Brno,
Czech Republic)

0603 PROPHYLACTIC VACCINATION WITH TUMOR – DERIVED MICROVESICLES AS A WAY TO PREVENT TUMOR DEVELOPMENT
M. Majka, A. Mordel (Jagiellonian University Medical College, Cracow,
Poland)

---

HOGDKIN'S LYMPHOMA

0604 PREDICTIVE VALUE OF EARLY PET DURING SALVAGE CHEMOTHERAPY IN RELAPSING/REFRACTORY HODGKIN’S LYMPHOMA (HL) PATIENTS
L. Castagna, S. Bramanti, M. Balzarotti, E. Todisco, B. Sarina,
A. Anastasia, M. Magagnoli, A. Nozza, R. Mazza, L. Giordano, A. Chiti,
A. Santoro (Istituto Clinico Humanitas, Rozzano, Italy)

0605 PHASE II STUDY OF THE HISTONE-DEACETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA PATIENTS
V. Bonfante, S. Viviani, C. Fasola, F. Crippa, A. Marchianò,
P. Valagussa, A.M. Gianni (Istituto Nazionale Tumori, Milan, Italy)

0606 REDUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN RELAPSED OR REFRACTORY HODGKIN’S DISEASE (HD): DISEASE STATUS AT TRANSPLANT IS A MAJOR FACTOR FOR OUTCOME
T. Gastinne, J. Delaunay, B. Mahe, V. Dubruille, N. Blin, S. Ayari,
S. Le Gouill, T. Guillaume, P. Chevalier, P. Moreau, J.-L. Harousseau,
M. Mothy (University Hospital of Nantes, Nantes, France)

0607 A NOVEL T(4;9)(Q21;P24) FUSES SEC31A TO JAK2 IN NODULAR-SCLEROSIS HODGKIN LYMPHOMA
K. Van Roosbroeck, I. Lahortiga, J. Cools, P. Vandenberghe, P. Marynen,
J. Delabie, C. De Wolf-Peeters, I. Wlodarska (Department of Human
Genetics, Catholic University of Leuven, Leuven, Belgium)

0608 DOSE-INTENSITY OF ABVD AS AN IMPORTANT PROGNOSTIC FACTOR FOR FIRST LINE HODGKIN DISEASE: AN ANALYSIS OF 107 CONSECUTIVE PATIENTS TREATED IN A SINGLE INSTITUTION
E. Nicolas-Virelizier, H. Ghesquieres, S. Dussart, B. Favier, F. Lachenal,
P. Biron, T. Gargi, C. Sebban (Centre Léon Bérard, Lyon, France)

0609 THE INFLUENCE OF THE POLYMORPHISM OF GLUTATHIONE S-TRANSFERASE PI 1 (GSTP1) GENE IN HODGKIN’S LYMPHOMA RISK AND PROGRESSION
G. Lourenco, I. Neri, V. Sforni, R. Kameo, I. Lorand-Metze, C. Lima
(State University of Campinas, Campinas, Brazil)

0610 DELIVERY OF FULL DOSE ABVD FOR HODGKIN’S LYMPHOMA WITHOUT GROWTH FACTORS AND REGARDLESS OF NEUTROPENIA DUE TO TREATMENT: A SAFE, EFFICACIOUS AND COST SAVING PRACTICE
J. Nangalia (Norfolk and Norwich University Hospitals NHS Trust,
Norwich, United Kingdom)

0611 PROGNOSTIC SIGNIFICANCE OF GLUTATHIONE-STRANSFERASE (GST) GENOTYPES IN PATIENTS WITH ADVANCED HODGKIN’ DISEASE (HD) ENROLLED IN THE HD2000 GISL TRIAL
M. Gentile, C. Mammì, L. Marcheselli, F. Merli, N. Cascavilla,
S. Luminari, C. Stelitano, M. Musso, E. Iannitto, F. Angrilli, M. Petrini,
A. Riezzo, S. Romito, G. Quarta, G. Partesotti, S. Molica, A. Fracasso,
G. Polimeno, M. Lombardo, M. Russo, F. Ilariucci, A. La Sala, S. Pozzi,
V. Callea, R Scalone, C. Laganà, M. Federico, F. Morabito (Ematologia
di Cosenza, Cosenza, Italy)

0612 PET/CT FINDINGS IN PATIENTS WITH HODGKIN´S LYMPHOMA (HL) AFTER ABVD COMBINATION CHEMOTHERAPY: CLINICAL AND PROGNOSTIC SIGNIFICANCE
T.P. Vassilakopoulos, S. Masouridis, M.K. Angelopoulou, S.I. Kokoris,
S. Sahanas, C. Kalpadakis, E.M. Dimitriadou, P. Tsirkinidis,
M. Moschoyiannis, P. Tsaftaridis, Z. Galanis, E. Variamis, A. Gouliamos,
V. Prassopoulos, L. Gogou, R. Eftimiadou, I. Andreou, K. Datseris,
C. Papavassiliou, G.A. Pangalis (National and Kapodistrian University
of Athens, Athens, Greece)

0613 CHEMOTHERAPY OR CHEMOTHERAPY PLUS RADIOTHERAPY IN EARLY HODGKIN’S LYMPHOMA ? FINAL RESULTS OF A RETROSPECTIVE ANALYSIS OF A REGIONAL ITALIAN EXPERIENCE
M. Clavio, F. Olcese, E. Rossi, M. Spriano, F. Ballerini, L. Canepa,
I. Pierri, S. Aquino, R. Varaldo, M. Cavaliere, A. Manna, V. Secondo,
O. Racchi, E. Balleari, S. Napoli, A.M. Carella, R. Ghio, M. Gobbi
(Hematology Inst., Genova, Italy)

0614 CHEST X-RAY(CXR) AND THORACIC CT SCAN EVALUATION OF MEDIASTINAL LYMPHADENOPATHY IN PATIENTS WITH HODGKIN 'S LYMPHOMA REVISITED
M.P. Angelopoulos, M. Angelopoulou, G. Pangalis, A. Gouliamos,
M. Siakantaris, S. Kokoris, E. Dimitriadou, M.-C. Kyrtsonis, P. Tsaftaridis,
E. Variamis, C. Kalpadakis, S. Sahanas, S. Masouridis, T. Vassilakopoulos
(National and Kapodistrian University of Athens, Athens, Greece)

0615 POSITRON EMISSION TOMOGRAPHY (PET) PERFORMED BEFORE ALLOGENEIC TRANSPLANTATION HAS A PROGNOSTIC ROLE IN PATIENTS WITH RELAPSED AND CHEMOSENSITIVE HODGKIN LYMPHOMA OR AGGRESSIVE NON-HODGKIN LYMPHOMA
A Dodero, R. Crocchiolo, F. Patriarca, L. Castagna, F. Ciceri,
N. Frungillo, R. Fanin, S. Bramanti, R. Miceli, A. Assanelli, R. Milani,
F. Crippa, P. Corradini (Istituto Nazionale dei Tumori, Milano, Italy)

0616 IS EARLY INTENSIFICATION USEFUL FOR PET2+ HL PATIENTS?
R. Sancetta, C. Fraulini, L. Rigacci, B. Puccini, P. Pregno, U. Vitolo,
E. Brusamolino, M. Gotti, M. Magagnoli, M. Balzarotti, A.M. Carella,
E. Rossi, A. Gallamini, T. Chisesi (O.C. Umberto I, Venezia Mestre, Italy)

0617 LEVELS OF CIRCULATING DNA IN THE PLASMA AT DIAGNOSIS ARE ASSOCIATED WITH CLINICAL CHARACTERISTICS AND PROGNOSIS IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMAS
S. Hohaus (Universita' Cattolica S. Cuore, Rome, Italy)

0618 DHAOX AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN’S AND NON HODGKIN’S LYMPHOMAS
L. Rigacci, A. Fabbri, B. Puccini, U. Vitolo, M. Lenoci, S. Mappa,
I. Chitarrelli, A. Levis, F. Lauria, A. Bosi (Azienda Ospedaliero
Universitaria Careggi, Florence, Italy)

0619 ASSOCIATION OF SERUM SELENIUM AT PRESENTATION, PATIENT CHARACTERISTICS AND OUTCOME IN HODGKIN AND FOLLICULAR LYMPHOMA
J.M. Stevens, R. Waters, C. Sieniawska, A. Rohatiner, J. Fitzgibbon,
S.P. Joel, T.A. Lister (St Bartholomew's Hopsital, Londonwest
Smithfield, United Kingdom)

0620 INTERMEDIATE DOSE GEMCITABINE – CISPLATIN COMBINATION CHEMOTHERAPY (GEMCIS) WITHOUT TREATMENT DELAY FOR CYTOPENIA - A NEW STANDARD IN PRE-AUTOGRAFT REMISSION INDUCTION FOR RELAPSED OR REFRACTORY HODGKIN'S DISEASE?
T. Todd, S. Raj, D. Camilleri, G. Stafford, G. Bulusu, G. Follows,
M. Williams, R. Marcus (Cambridge University Hospitals NHS
Foundation Trust, Cambridge, United Kingdom)

---

INHERITED ANEMIAS: SICKLE CELL DISEASE AND RED CELL MEMBRANE DISORDERS

0621 COMPARISON OF THE EOSIN-5-MALEIMIDE FLOW CYTOMETRIC METHOD WITH OSMOTIC FRAGILTY TEST USED IN DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS
P. Bianchi, E. Fermo, C. Vercellati, A.P. Marcello, A. Zanella,
A. Cattaneo, W. Barcellini (Fondazione IRCCS OMPMARE, Milano,
Italy)

0622 USEFULNESS OF TWO NEW METHODS - FLOW CYTOMETRY (FC)AND CRYOHEMOLYSIS (CH) TESTS - FOR THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS (HS): COMPARISON WITH STANDARD SCREENING TESTS
L. Crisp, C. Donato, B. Venegas, E. Chamorro, A. Solari, D. Vota,
D. Gammela, G. Miguez, A. Schvartzman, D. Vittori, S. Caldarola,
G. Alfonso, A. Nesse (Hospital Nacional A.Posadas, Buenos Aires,
Argentina)

0623 PARADOXICAL HYDROXYUREA STIMULATION OF PRO-INFLAMMATORY CYTOKINE GENES EXPRESSION IN ENDOTHELIAL CELLS: RELEVANCE TO SICKLE CELL DISEASE
S. Laurance, O. Dossou-Yovo, A. Benecke, F.X. Pellay, E. Verger,
R. Krishnamoorthy, J. Elion, C. Lapoumeroulie (INSERM,
U763-Université Paris 7 Denis Diderot, Paris, France)

0624 PREDICTORS OF NOCTURNAL OXYHAEMOGLOBIN DESATURATION IN CHILDREN WITH SICKLE CELL DISEASE
J. Kirkham, O. Wilkey, D.K.M. Hewes, J.P.M. Evans (UCL Institute of
Child Health, London, United Kingdom)

0625 OVERNIGHT OXYHAEMOGLOBIN DESATURATION PREDICTS ABNORMAL TRANSCRANIAL DOPPLER IN SICKLE CELL ANAEMIA
J. Kirkham, P. Telfer, R.S. Bucks, D.K.M. Hewes, B. Kaya, M. Prengler,
I. Dundas, R. Lane, S. Carr, J.P.M. Evans (UCL Institute of Child Health,
London, United Kingdom)

0626 BONE MINERAL DENSITY IN CHILDREN WITH SICKLE CELL DISEASE (SCD)
M de Montalembert, E. Chapelon, V. Brousse, J.C. Souberbielle,
J.L. Bresson, M. Garabedian, M. De Montalembert (Hopital Necker,
Paris, France)

0627 UGT1A1 GENE VARIATIONS & GALLSTONES IN SICKLE CELL DISEASE PATIENTS FROM SULTANATE OF OMAN
V. Pathare, S. Alkindi, S. AlZadjali, V.K. Panjwani, D. Dennison,
R. Krishnamoorthy (Sultan Qaboos University, Muscat, Oman)

0628 ENALAPRIL THERAPY IN CARDIAC REMODELLING OF SICKLE CELL DISEASE PATIENTS
C. Lima, O. Ueti, A. Ueti, K. Franchini, F. Costa, S. Saad
(State University of Campinas, Campinas, Brazil)

0629 SIX YEARS FOLLOW-UP OF HYDROXUREA TREATMENT IN YOUNG ALGERIAN PATIENTS WITH SICKLE CELL DISEASE
M. Bradai, F. Talbi, F. Lamraoui, S.A. Oukrif, F.Z. Ardjoun (Institute of
Medicin of Blida, Blida, Algeria)

0630 GENERALIZED RADIOLOGICAL ABNORMALITY ASSOCIATED WITH ACUTE NEUROLOGICAL PRESENTATIONS IN SICKLE CELL DISEASE
J. Kirkham, P.B.D. Inusa, K. Pohl, M. Bynevelt, T.C. Cox, W.K. Chong,
D.E. Saunders, M. Prengler (UCL Institute of Child Health, London,
United Kingdom)

0631 ELEVATED NUMBERS OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN SICKLE CELL DISEASE
E. Nur, R.T. van Beem, A.J. Duits, E.J. van Beers, H. C. de Boer,
B.J. Biemond, J.J. Zwaginga (Academic Medical Center, Amsterdam,
The Netherlands)

0632 REDUCED CO2-INDUCED CEREBRAL VASOMOTOR REACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE
E. Nur, Y. Kim, J. Truijen, E.J. van Beers, S.C.A.T. Davis, B.J. Biemond,
J.J. van Lieshout (Academic Medical Center, Amsterdam,
The Netherlands)

0633 SCREENING FOR HAEMOGLOBINOPATHY IN NORTHERN GREECE – EPIDEMIOLOGICAL SURVEY
S. Theodoridou, M. Alemayehou, P. Perperidou, V. Aletra,
T. Karakasidou, P. Lazaridou, T. Vyzantiadis, A. Manitsa, A. Stamna,
L Papayiannis (Hippokration Hospital, Thessaloniki, Greece)

0634 MID-TERM EFFICACY OF SUBTOTAL SPLENECTOMY IN YOUNG CHILDREN WITH HEREDITARY SPHEROCYTOSIS
R.Y.J. Tamminga, P.M.A. Broens (University Medical Centre Groningen,
Groningen, The Netherlands)

0635 PULMONARY HYPERTENSION IN CHILDREN AND YOUNG ADULTS WITH SICKLE CELL DISEASE: LACK OF RESPONSE TO HYDROXYUREA AND EVIDENCE FOR FAMILIAL CLUSTERING
M. Hayek, H. Dahoui, F. Bitar, S. Muwakkit, I. Dabbous, M. Arabi,
P. Nietart, M. Abboud (Children's Cancer Center of Lebanon, Beirut,
Lebanon)

---

MULTIPLE MYELOMA - CLINICAL II

0636 LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
A. Palumbo, P. Falco, G. Sanpaolo, A. Falcone, V. Ferderico, L. Canepa,
M. Crugnola, L. Baldini, S. Caltagirone, A. Larocca, F. Gay, V. Magarotto,
M.T. Petrucci, M. Boccadoro (A.O.U. San Giovanni Battista, Torino, Italy)

0637 RESULTS OF A PHASE I/II TRIAL OF DEUTSCHE STUDIENGRUPPE MULTIPLES MYELOM , SHOWING EFFICACY AND SAFETY OF RAD REGIMEN (REVLIMID ®, ADRIAMYCIN ®, DEXAMETHASONE)IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA
S. Knop, C. Gerecke, P. Liebisch, M.S. Topp, U. Platzbecker, C. Vollmuth,
H. Einsele, R. Bargou (Wuerzburg University Hospital, Wuerzburg,
Germany)

0638 EFFECT ON SURVIVAL OF LENALIDOMIDE AND DEXAMETHASONE ASSOCIATED DEEP VEIN THROMBOSIS (DVT)IN RELAPSED MULTIPLE MYELOMA PATIENTS
M. Zangari, L. Fink, R. Knight, T. Cavanaugh, D. Weber, R. Niesvizky,
G. Tricot (University of Utah, Salt Lake City, USA)

0639 EXPANDED ACCESS PROGRAM (EAP)FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
A. Palumbo, F. Gay, G. Buda, T. Guglielmelli, G. Perrone, P. Corradini,
F. Benedetti, M. Offidani, D. Rossi, A. Gozzetti, L. Catalano, L. Canepa,
F. Di Raimondo, F. Patriarca, M.T. Petrucci, N. Di Renzo, M. Galli,
F. Cavallo, S. Bringhen, M. Boccadoro (A.O.U. San Giovanni Battista,
Torino, Italy)

0640 PHASE I TRIAL OF ORAL VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN ADVANCED MULTIPLE MYELOMA
D.M. Weber, S. Jagannath, A. Mazumder, R. Sobecks, G.J. Schiller,
M. Gavino, K. Meehan, C. McFadden, C. Chen, J.L. Ricker, S. Rizvi,
C. Oerth, P. Brownell, C. Sanz-Rodriguez, M.A. Hussein (MD Anderson
Cancer Center, Houston, USA)

0641 ROLE OF THALIDOMIDE ON VELCADE NEUROPATHY IN MYELOMA PATIENTS
T. Caravita, A. Siniscalchi, A. Spagnoli, M.T. Petrucci, F. Vincenzo,
P. Falco, M. Offidani, M. Rizzo, A. Palumbo, P. De Fabritiis (S.Eugenio
Hospital, Rome, Italy)

0642 PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)PATIENTS (PTS)
Z. Badros, S. Philip, R. Niesvizky, O. Goloubeva, C. Harris, J. Zweibel,
J. Wright, A. Burger, M. Baer, M. Egorin, S. Grant (University of
Maryland, Baltimore, Md, USA)

0643 PHASE II TRIAL WITH PLITIDEPSIN (APLIDIN) ALONE AND IN COMBINATION WITH DEXAMETHASONE (DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; PROMISING ACTIVITY WITH MANAGEABLE TOXICITY
M.V. Mateos, M.V. Mateos, M.T. Cibeira, J. Bladé, P.G. Richardson,
F. Prosper, A. Oriol, J. de la Rubia, A. Alegre, J.J. Lahuerta,
R. García-Sanz, J. Espinoza, K. Mitsiades, K. Anderson, J.F. San
Miguel (University Hospital of Salamanca, Salamanca, Spain)

0644 BORTEZOMIB-RELATED PERIPHERAL NEUROPATHY:AN IMPORTANT BUT REVERSIBLE SIDE EFFECT OF THERAPY. A STUDY ON 105 MULTIPLE MYELOMA PATIENTS
S. Mangiacavalli, A. Corso, M. Varettoni, L. Barbarano, D. Petrò,
E. Morra, M. Lazzarino (Fondazione IRCCS Policlinico S. Matteo,
UNiversity of Pavia, Pavia, Italy)

0645 RESPONSE TO BORTEZOMIB RETREATMENT IS DETERMINED BY DURATION OF PRECEDING TREATMENT FREE INTERVAL - RESULTS FROM A RETROSPECTIVE MULTICENTER SURVEY
I. Hrusovsky, B. Emmerich, M. Engelhardt, G. Hess, M. Kornacker
(St. Joseph Hospital, Bremerhaven, Germany)

0646 A PHASE I DOSE ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE OF CYCLOPHOSPHAMIDE WHEN GIVEN IN COMBINATION WITH DEXAMETHASONE AND LENALIDOMIDE IN RELAPSE/REFRACTORY MULTIPLE MYELOMA
S. Schey, G. Morgan, F. Davies, K. Phekoo, K. Ramasamy, M. Jenner,
B. Hazel (King's College Hospital, London, United Kingdom)

0647 ELPHALAN-DEXAMETHASONE IN PATIENTS WITH AL AMYLOIDOSIS NOT ELIGIBLE FOR HIGH-DOSE MELPHALAN THERAPY
S.O. Schönland, S. Dietrich, U. Hegenbart, T. Bochtler, A.V. Kristen,
H. Goldschmidt, A.D. Ho, S.O. Schönland (University of Heidelberg,
Heidelberg, Germany)

0648 MOBILISATION FAILURE IS PREDICTIVE OF POOR OVERALL SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION
K. Ramasamy, S. Mahmood, Z.Y . Lim, A. Mijovic, S. Devereux,
A. Pagliuca, G.J. Mufti, S. Schey (Kings College Hospital, London,
United Kingdom)

0649 RESPONSE TO RE-TREATMENT ON RELAPSE MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB
A. Rubio-Martinez, V. Recasens, B. Soria, M.A. Montañes, R. Rubio-
Escuin, P. Giraldo (Miguel Servet University Hospital, Zaragoza, Spain)

0650 VAMP/THACYDEX: VELCADE (BORTEZOMIB), ADRIAMYCIN, MELPHALAN AND PREDNISONE ALTERNATING WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETASONE AS A SALVAGE REGIMEN IN RELAPSED MULTIPLE MYELOMA PATIENTS: A SPANISH MYELOMA GROUP (GEM/PETHEMA) STUDY
E. Colado, M.V. Mateos, M.J. Moreno, F. De Arriba, J. De la Rubia,
P. Iniesta, M.C. Viguria, R. Garcia-Sanz, J. Olazabal, J.F. San Miguel
(Hospital Universitario de Salamanca, Salamanca, Spain)

0651 PRETREATMENT WITH THALIDOMIDE AND BORTEZOMIB DOES NOT INFLUENCE RESPONSE TO LENALIDOMIDE IN RELAPSED MYELOMA. PRELIMINARY RESULTS FROM PATIENTS INCLUDED IN DUTCH COMPASSIONATE NEED PROGRAMME
E. Kneppers, H.M. Lokhorst, C. Eeltink, R. Raymakers, R. Schaafsma,
P. Sonneveld, E. Vellenga, S. Wittebol, P. Wijermans, S. Zweegman
(UMC Utrecht, Utrecht, The Netherlands)

0652 THALIDOMIDE-DEXAMETHASONE (THALDEX) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS RELAPSING AFTER HIGH DOSE THERAPY AND AUTOPBSCT
G. Charlinski, M. Barwicka, E. Wiater, J. Dwilewicz-Trojaczek,
W. Wiktor-Jedrzejczak (Medical University, Warsaw, Poland)

0653 PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
M.C. Kyrtsonis, T.P. Vassilakopoulos, S. Sachanas, G. Panagoulias,
V. Bartzis, K. Anargyrou, M. Dimou, T. Tzenou, S. Masouridis,
C. Kalpadakis, E. Dimitrakopoulou, S.I. Kokoris, E. Dimitriadou,
M.P. Siakantaris, M.K. Angelopoulou, P. Panayiotidis, G.A. Pangalis
(University of Athens, Athens, Greece)

0654 THE EFFICACY AND SAFETY OF PAD REGIMEN (BORTEZOMIB, DOXORUBICIN, DEXAMETHASONE) IN THE TREATMENT OF PLASMA CELL LEUKEMIA
M. Kraj, R Poglod, T Szpila, K. Warzocha (Institute of Hematology and Transfusion Medicine, Warsaw, Poland)

0655 SAFE AND EFFECTIVE MOBILIZATION OF STEM CELLS IN MULTIPLE MYELOMA FOLLOWING PRIMING BY HIGH-DOSE CYCLOPHOSPHAMIDE AND BORTEZOMIB
G. Mikala (St Istvan & St Laszlo Hospital of Budapest, Budapest,Hungary)

---

MULTIPLE MYELOMA - CLINICAL III

0656 PAD (BORTEZOMIB/ADRIAMYCIN/DEXAMETHASONE) REGIMEN IS VERY EFFECTIVE IN HIGH RISK, NEWLY-DIAGNOSED MYELOMA, REDUCES DICKKOPF- 1 AND ABNORMAL BONE RESORPTION AND NORMALIZES IMPAIRED ANGIOPOIETIN-1/-2 RATIO
E. Terpos, I. Baltathakis, K. Anargyrou, S. Delimpasi, E. Kastritis,
A. Christoforidou, K. Tsionos, K. Tsatalas, E. Nikiforakis,
M.A. Dimopoulos, N. Harhalakis (251 General Air Force Hospital,
Athens, Greece)

0657 DETERMINING THE EXTENT OF DISEASE WITH MAGNETIC RESONANCE IMAGING OF THE BONE MARROW (BM-MRI) IN PATIENTS WITH MULTIPLE MYELOMA
S. . Ailawadhi, A.N. Abdelhaleim, L. Derby, T.L. Mashtare, G. Wilding,
K.C. Miller, R. Gottleib, S. Padmanabhan, R.A. Alberico,
D.L. Klippenstein, K. Lee, A. Chanan-Khan (Roswell Park Cancer
Institute, Buffalo, United States of America)

0658 DICKKOPF 1 PROTEIN LEVELS IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
G.B. Lobreglio, A. Gatto, P. Capuani, P. Verardo, E. Chiuri, D. Turco,
G. Pasanisi (A.O. "Card G. Panico", Tricase, Italy)

0659 BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE
P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Ceccolini, A. Brioli,
M. Pallotti, L. Pantani, A. Petrucci, M. Baccarani, M. Cavo (Seragnoli
Institute of Hematology and Medical Oncology, Bologna, Italy)

0660 THE BONE DEGRADATION MARKER CTX-I SHOWS UNIQUE PROPERTIES COMPARED TO NTX-I AND ICTP WHEN USED FOR CONSECUTIVE MEASUREMENTS IN PATIENTS WITH MULTIPLE MYELOMA
T. Lund, J.M. Delaissé, N. Abildgaard, K. Kupisiewicz, T. Plesner (Vejle Hospital, Vejle, Denmark)

0661 A SINGLE-CENTRE LONGITUDINAL STUDY ON 1003 MULTIPLE MYELOMA PATIENTS TO EVALUATE THE INCIDENCE, PRESENTING FEATURES AND PROGNOSIS OF EXTRAMEDULLARY MYELOMA
M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto,
M. Lazzarino (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0662 ANALYSIS OF THE INVOLVED IGGA / IGGA RATIOS MAY GIVE A MORE SENSITIVE MEASURE OF RESPONSE TO TREATMENT IN MULTIPLE MYELOMA
S.J. Harding, M. Drayson, J. Hobbs, G. Mead, A. Bradwell (The Binding Site, Birmingham, United Kingdom)

0663 HYPOADIPONECTINEMIA IS ASSOCIATED WITH MULTIPLE MYELOMA RISK
M. Dalamaga, A. Lekka, M. Triantafilli, K. Karmaniolas, A. Hsi,
A. Panagiotou, C. Dimas, C. Mantzoros (Athens University Medical School, Athens, Greece)

0664 THYROID AUTOIMMUNITY AND THE OCCURRENCE OF MULTIPLE MYELOMA
M. Dalamaga, M. Triantafilli, K. Karmaniolas, N. Pelekanos,
G. Sotiropoulos, A. Lekka (Athens University Medical School, Athens, Greece)

0665 THE ROLE OF PARAPROTEIN ON PLATELET DISFUNCTION
D.I. Djunic, E.I. Elezovic, M.N. Milosevic-Jovcic, I.V. Ilic, S.N.
Suvajdzic-Vukovic, B.J. Bila, V.A. Vidovic, A.D. Antic, T.D. Tomin (Institute of Haematology, Clinical Center of Serbia, Belgrade, Serbia)

0666 SUCCESFUL PREVENTION OF OSTEONECROSIS OF THE JAW DURING ZOLENDRONAT USE IN THE PATIENTS WITH MULTIPLE MYELOMA
R. Hajek, L. Pour, Z. Adam, M. Krejci, A. Krivanova, L. Zahradova,
V. Sandecka (Masaryk university Brno, Faculty hospital, Brno,Czech Republic)

0667 BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL
S. Pozzi, R. Marcheselli, S. Sacchi, L. Baldini, F. Angrilli, S. Falorio,
G. Quarta, C. Stelitano, G. Caparotti, S. Luminari, A. Falcone, D. Natale,
Ch. Broglia, A. Cuoghi, D. Dini, P. Ditonno, G. Leonardi, G. Pianezze,
V. Pitini, G. Polimeno, L. Ponchio, L. Masini, M. Maurizio, M. Spriano,
P. Musto (Università di Modena e Reggio Emilia, Modena, Italy)

0668 NOVEL NEPHELOMETRIC IMMUNOASSAYS FOR THE SENSITIVE DETECTION OF IGA MONOCLONAL GAMMOPATHIES IN MULTIPLE MYELOMA AND AL AMYLOIDOSIS
S.J. Harding, M. Drayson, H. Lachmann, P. Hawkins, J. Hobbs, G. Mead,
A. Bradwell (The Binding Site, Birmingham, United Kingdom)

0669 FAMILIAL B-CELL LYMPHOPROLIFERATIVE DISEASES: HYPER-RESPONSIVE B-CELLS IN UNAFFECTED FAMILY MEMBERS
H. Steingrimsdottir, H.K. Einarsdottir, V. Haraldsdottir,
H.M. Ogmundsdottir (Landspitali University Hospital, Reykjavik, Iceland)

0670 ANALYSIS OF DISTINCT MULTIPLE MYELOMA SUBGROUPS BASED ON BIOLOGICAL CHARACTERISTICS, BONE MARROW MICROENVIRONMENT AND INTERNATIONAL STAGING SYSTEM
J. Bila, I. Elezovic, M. Perunicic, N. Suvajdzic-Vukovic, M. Todorovic,
D. Tomin, A. Vidovic, B. Mihaljevic, M. Gotic, D. Boskovic (Institute of Hematology, Belgrade, Serbia)

0671 THE INCIDENCE OF JAW OSTEONECROSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH BISPHOSPHONATES
M. Kraj, R. Poglod, M. Maj, K. Owczarska (Institute of Hematology and
Transfusion Medicine, Warsaw, Poland)

0672 INCIDENCE OF LIGHT CHAIN ESCAPE IN UK MRC MYELOMA VII TRIAL
A.R. Hobbs, K. Sharp, S.J. Harding, M. Drayson, A.R. Bradwell,
G.P. Mead (The Binding Site, Birmingham, United Kingdom)

0673 A RANDOMISED CONTROLLED TRIAL OF AN EDUCATIONAL BOOKLET FOR MULTIPLE MYELOMA PATIENTS WITH PERIPHERAL NEUROPATHY
H.L. Clarke, R. Gillibrand (University of the West of England, Bristol, United Kingdom)

0674 PLASMA HOMOCYSTEINE AND METHYLMALONIC ACID CORRELATE TO RENAL FUNCTION AND NOT TO PLASMA COBALAMIN (VITAMIN B12) IN MULTIPLE MYELOMA PATIENTS
N.E.U. Hermansen, U. Malm, P. Gimsing (Rigshospitalet, Copenhagen, Denmark)

---

MYELODYSPLASTIC SYNDROMES - BIOLOGY

0675 A NOVEL APPROACH FOR STUDYING CLONAL GRANULOPOIESES IN MDS – MONITORING THE INFLUENCE OF IMIDS
K. Püllmann, A. Ganser (Hannover Medical School, Hannover, Germany)

0676 AML1/RUNX1 MUTATIONS COOPERATE WITH CLASS I MUTATIONS IN THE PROGRESSION OF MDS TO S-AML FOLLOWING MDS IN NORMAL KARYOTYPE
S. Dicker, C. Haferlach, W. Kern, T. Haferlach, S. Schnittger
(MLL Munich Leukemia Laboratory, Munich, Germany)

0677 THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND MATRIX METALLOPROTEINASE 2 AND 9 OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME
R. Invernizzi, E. Travaglino, V. Matti, M.G. Della Porta, L. Malcovati,
A. Gallì, E. Bonetti, E. Boveri, V. Rosti, M. Cazzola (Fondazione IRCCS
Policlinico S. Matteo, Pavia, Italy)

0678 EPIGENETIC REGULATION OF FAS EXPRESSION ALONG PROGRESSION OF MYELODYSPLASTIC SYNDROMES
B. Fontenay, B. Benet, M. Gentil, E. Gyan, E. Frisan, C. Pierre-Eugene,
C. Humbrecht, F. Picard, M. Guesnu, V. Bardet, O. Beyne-Rauzy,
M. Hunault-Berger, B. Quesnel, E. Solary, C. Lacombe, P. Mayeux,
F. Dreyfus (Cochin Institute, Paris, France)

0679 DEFECTIVE SUPPRESSOR ACTIVITY AND BONE MARROW TRAFFICKING OF TREGS IN EARLY-STAGE MDS
I. Kotsianidis, I. Bouchliou, E. Spanoudakis, E. Nakou, D. Margaritis,
A.V. Christophoridou, A. Anastasiades, C. Tsigalou, G. Kambouromiti,
G. Bouricas, C. Tsatalas (Democritus University of Thrace,
Alexandroupolis, Greece)

0680 REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 10 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
B.P. Bernasconi, I. Dambruoso, M. Boni, R. Zappatore, P.M. Cavigliano,
I. Giardini, S. Calatroni, B. Rocca, M. Caresana, P. Tarantino,
M. Lazzarino (Foundation IRCCS Policlinico San Matteo, Pavia, Italy)

0681 GENETIC IMBALANCES IN MYELODYSPLASTIC SYNDROMES(MDS) AND ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH CHROMOSOME 11Q13 ABNORMALITIES
B.P. Bernasconi, I. Dambruoso, M. Boni, R. Zappatore,
P.M. Cavigliano, I. Giardini, M. Caresana, P. Tarantino, R. Invernizzi,
M. Lazzarino (Foundation IRCCS Policlinico San Matteo, Pavia, Italy)

0682 DYNAMICS OF TELOMERE LENGTH, THE STATUS OF CDKN2B GENE METHYLATION AND TELOMERASE ACTIVITY AS A POTENTIAL UNSPECIFIC PROGNOSTIC MARKERS IN MDS
S. Vcelikova, H. Cechova, H. Zizkova, P. Baresova, M. Skalova,
Z. Zemanová, K. Michalová, J. Cermak (Institution of Hematology
and Blood Transfusion, Prague, Czech Republic)

0683 LENALIDOMID INFLUENCES THE T-CELL RECEPTOR REPERTOIRE IN PATIENTS WITH 5Q- MYELODYSPLASTIC SYNDROME
T. Momot, C. Dobbelstein, J. König, O. Schulz, J.-E. Pautsch, A. Ganser,
E.M. Weissinger (Medical School Hannover, Hannover, Germany)

0684 PI3K, FLT3, JAK2 MUTATIONS AND MDM2 POLYMORPHISM IN BRAZILIAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
F. Traina, P. Campos, M. Andreoli, J.A. Machado Neto,
K.B.B. Pagnano, I. Lorand-Metze, F.F. Costa, S.T.O. Saad
(State University of Campinas, Campinas, Brazil)

0685 T CELL MEDIATED AUTOLOGOUS CYTOTOXICITY AGAINST HEMATOPOIETIC PRECURSOR CELLS IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
M.E.D. Chamuleau, T.M. Westers, J. Groenland, L. Dreunen,
A. Zevenbergen, G.J. Ossenkoppele, A.A. van de Loosdrecht
(VU University Medical Center, Amsterdam, The Netherlands)

0686 EXPRESSION ANALYSIS OF DNA REPAIR ENZYMES OF THE NON HOMOLOGOUS END JOINING MECHANISM IN THE BONE MARROW OF ADULT DE NOVO MYELODYSPLASTIC
P. Economopoulou, F. Kontsioti, V. Pappa, E. Ioannidou,
S. Chondropoulos, S. Papageorgiou, K. Girkas, V. Giannopoulou,
E. Papageorgiou, J. Dervenoulas, T. Economopoulos (Attikon
University General Hospital, Athens, Greece)

0687 CYTOGENETIC AND IMMUNOREGULATORY PROPERTIES OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
M. Klaus, P. Fragioudaki, K. Giannikou, M. Ximeri, M. Psyllaki,
C. Kastrinaki, H. Papadaki (University of Crete School of Medicine,
Heraklion, Crete, Greece)

0688 WT1 AND CXCR4 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
I.S. Improta, M.R. Villa, A. Lucania, M.R. Esposito, M. Sagristani,
N. Pepe, P. Rotondo, M. Sansone, M.T. Polistina, L. Mastrullo
(P.O. San Gennaro U.O.C. Ematologia, Napoli, Italy)

0689 EXPRESSION AND REGULATION OF KILLER CELL IMMUNOGLOBULIN (IG)-LIKE RECEPTORS (KIR) IN 5Q-MYELODYSPLASTIC SYNDROMES (MDS)
T. Momot, C. Dobbelstein, J. König, O. Schulz, J.-E. Pautsch, A. Ganser,
E.M. Weissinger (Medical School Hannover, Hannover, Germany)

0690 STUDY OF BONE MARROW HAEMOPOIESIS AND PERIPHERAL BLOOD LYMPOCYTE SUBSETS IN PATIENTS WITH MYELOSDYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
M. Ximeri, A. Galanopoulos, A. Symeonidis, Z. Kartasis, V. Pappa,
D. Liapi, E. Hatzimichael, S. Kokoris, K. Giannikou, M. Psyllaki,
M. Klaus, H. Papadaki (University of Crete School of Medicine,
Heraklion, Crete, Greece)

0691 INTRONIC RNA EXPRESSION IN STROMAL CELLS OF PATIENTS

WITH MYELODYSPLATIC SYNDROME BY RNA MICROARRAY ANALYSIS
M.O. Baratti, Y.B. Moreira, F. Traina, L. Borges, F.F. Costa,
S. Verjovski-Almeida, S.T.O. Saad (Hematology and Hematherapy Center / State University of Campinas, Campinas, Brazil)

0692 EVALUATION OF GENE METHYLATION STATUS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: NEW PROGNOSTIC MARKERS?
E.N. Cortesao, A.C. Gonçalves, M.I. Sousa, C. Moucho, M.A. Pereira,
J. Nascimento Costa, A.B. Sarmento (University Hospital of Coimbra, Coimbra, Portugal)

---

MYELODYSPLASTIC SYNDROMES - CLINICAL II
0693 IRON OVERLOAD AND CHELATION THERAPY PATTERNS IN LOW RISK MYELODYSPLATIC SYNDROMES WITH TRANSFUSION REQUIREMENTS. A CROSS SECTIONAL OBSERVATIONAL NATIONAL STUDY IN SPAIN (IRON STUDY)
F. Remacha, B. Arrizabalaga, C. Del Cañizo, G. Sanz, A. Villegas
(Hospital de Sant Pau, Barcelona, Spain)

0694 EFFICIENCY AND SAFETY OF ADMINISTRATION OF ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH EARLY MYELODYSPLASTIC SYNDROME (MDS)
J. Cermak, A. Jonasova, J. Vondrakova, L. Walterova, M. Siskova,
I. Hochova, R. Neuwirtova (Institute of Hematology and Blood
Transfusion, Praha, Czech Republic)

0695 EFFICACY OF THE FLAG-IDA REGIMEN AS FIRST LINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM A SINGLE CENTER
M. Bernardi, M. Tassara, A. Crotta, C. Messina, J. Peccatori,
A. Assanelli, D. Clerici, S. Mastaglio, F. Ciceri (San Raffaele Scientific
Institute, Milan, Italy)

0696 EQUIBALENT EFFICACY OF AZACITIDINE FOR PATIENTS WITH POOR CYTOGENETICS AND HIGH RISK MYELODYSPLASTIC SYNDROME
D.Y. Kim, M.J. Jang, J.H. Won, Y.K. Kim, J.S. Ahn, S.H. Bae, H.J. Shin,
I. Kim, H.M. Ryoo, J.H. Lee, S.J. Choi, Y.C. Mun, S.S. Yoon, D. Oh,
J.H. Lee, H.K. Lee, K.H. Lee, H.J. Kim, S. Park, Y.H. Min, B.K. Kim,
S.M. Bang, J.H. Lee (Asan Medical Center, Seoul, South-Korea)

0697 BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES?
S. Galimberti, M. Canestraro, H. Savli, G. A. Palumbo, B. Nagy,
F. Di Raimondo, M. Petrini (Hematology, Pisa, Italy)

0698 THE TCR REPERTOIRE OF PATIENTS WITH MYELODYSPLASIA DISPLAYS A HIGH FREQUENCY OF SELECTIVE EXPANSIONS IN BOTH CD4+ AND CD8+ T-CELLS ALONG WITH A DRAMATIC CONTRACTION CONFINED TO THE CD8+ SUBSET
C. Fozza, S. Contini, A. Galleu, M.P. Simula, M. Longinotti
(University of Sassari, Sassari, Italy)

0699 USAGE PATTERNS AND TRANSFUSION REQUIREMENTS IN PATIENTS ENROLLED IN AVIDA, A LONGITUDINAL REGISTRY OF PATIENTS WITH HEMATOLOGIC DISORDERS RECEIVING AZACITIDINE
L. Grinblatt, X. Narang, M. Malone, A. Sweet, S. Dunne, A. Sullivan
(Evanston Northwestern Healthcare, Evanston, USA)

0700 REVISITING GVL EFFECT OF AZACITIDINE TREATMENT IN RELAPSED MDS PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
S.G. Cho, S.Y. Kim, B.S. Cho, M. Kim, K.S. Eom, Y.J. Kim, H.J. Kim,
S. Lee, C.K. Min, D.W. Kim, J.W. Lee, W.S. Min, J.W. Park, C.C. Kim
(Catholic University of Korea, Seoul, South-Korea)

0701 TWICE-WEEKLY HIGH-DOSE RHUEPO FOR THE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
R. Latagliata, E.N. Oliva, P. Volpicelli, I. Carmosino, M. Breccia,
I. Vincelli, C. Alati, L. Napoleone, F. Vozella, F. Nobile, G. Alimena
(Hematology- University "La Sapienza", Rome, Italy)

0702 AZACITIDINE IN COMBINATION WITH EPO+G-CSF AND VALPROIC ACID RAPIDLY DETERMINES HEMATOLOGICAL IMPROVEMENT IN PRETREATED NON RESPONSIVE IPSS INT-1 MDS PATIENTS
V. Santini, A. Gozzini, T. Lunghi, A. Bosi (University of Florence,
Firenze, Italy)

0703 ERYTHROPOIETIN (EPO) THERAPY AND MYELODYSPLASTIC SYNDROME (MDS): SEARCHING FOR A COMMON IMMUNOPHENOTYPE IN RESPONDERS
P. Font, D. Subirá, J. Loscertales, L. Villalón, S. Ramiro, C. Aláez,
C. Serrano, C. Martínez-Chamorro, A. Escudero, J.M. Fernández-
Rañada (Clinica Moncloa, Madrid, Spain)

0704 DEFERASIROX IS THE ONLY IRON CHELATOR ACTING AS A POTENT NF-KB INHIBITOR IN MDS CELLS AND LEUKEMIC CELL LINES
E. Messa, R. Catalano, V. Rosso, F. Messa, F. Arruga, I. Defilippi,
S. Carturan, A. Rotolo, D. Gioia, E. Bracco, A. Roetto, A. Levis,
C. Camaschella, G. Saglio, D. Cilloni (University of Turin, Turin, Italy)

0705 POLYMORPHISMS OF GSTP1, GSTM1, GSTT1 AND NQO1 GENES IN PATIENTS WITH TREATMENT - RELATED MYELODYSPLASTIC SYNDROME OR ACUTE LEUKEMIA
E. Georgiou, M. Papaioannou, F. Samarah, J. Christakis, N. Vavatsi -
Christaki (Dept. of Biochemistry, School of Medicine, Aristotle
University of Thessaloniki, Thessaloniki, Greece)

0706 GENOME-WIDE COPY NUMBER ANALYSIS IN CHILDHOOD MDS USING ARRAY-CGH
I. Praulich, C. Kratz, C. Flotho, G. Göhring, P. Lichter, C. Niemeyer,
B. Schlegelberger, D. Steinemann (Hannover Medical School,
Hannover, Germany)

---

MYELODYSPLASTIC SYNDROMES - DIAGNOSTIC
0707 EUROPEAN LEUKEMIANET (ELN) PROJECT DIAGNOSTIC PLATFORM (WP10): PRELIMINARY RESULTS OF THE EUROPEAN MORPHOLOGY CONSENSUS PANEL
G. Zini, B. Bain, G. Castoldi, J. Cortez, J. Csomor, E. Faber,
A. Giagounidis, T. Haferlach, P. Kacirkova, K. Lewandowski, V. Liso,
E. Matutes, M. Maynadie, J. Meletis, A. Porwit, M.L. Ribeiro, L. Sréter,
A. Tichelli, T. Vallespì, M.B. Van 't Veer, S. Woessner Casas, M.C. Béné
(Catholic University Sacred Heart, Rome, Italy)

0708 CLINICAL AND PROGNOSTIC CHARACTERISTICS OF 484 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME (T-MDS) OR ACUTE MYELOID LEUKEMIA (T-AML)
A.K. Kündgen, D. Haase, A. Giagounidis, S. Blum, S. Fischer,
U. Platzbecker, R. Schlenk, B. Hildebrandt, P. Valent, M. Stadler,
R. Stauder, O. Krieger, K. Götze, W.K. Hofmann, A. Ganser, C. Mende,
R. Haas, N. Gattermann, U. Germing (Heinrich-Heine University,
Düsseldorf, Germany)

0709 INFLUENCE OF HISTOLOGICAL BONE MARROW FINDINGS ON OUTCOME IN 1175 PATIENTS SUFFERING FROM MYELODYSPLASTIC SYNDROME
S. Blum, S. Baghikar, S. Braunstein, P. Reinecke, A. Schmidt-Gräff,
M. Schapira, U. Germing (Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland)

0710 DYSPLASTIC FEATURES DETECTED BY MULTIPARAMETER FLOW CYTOMETRY AND THEIR RELATION TO CYTOMORPHOLOGIC AND CYTOGENETIC FINDINGS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
W. Kern, C. Haferlach, S. Schnittger, T. Haferlach (MLL Munich
Leukemia Laboratory, Munich, Germany)

0711 MAJOR DIFFERENCES WITH SCORING KARYOTYPE RESULTS FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING IPSS CRITERIA: A CALL FOR INTERNATIONAL STANDARDIZATION
A.M.M.J. Hagemeijer, K. Chun, A. Iqbal, G. Dewald, M.L. Slovak
(University of Leuven, Leuven, Belgium)

0712 DO PROGNOSTIC INDICES IN MDS LOSE THEIR PREDICTIVE POWER OVER TIME?
H. Tuechler, T. Noesslinger, A. Makrai, E. Pittermann, M. Pfeilstoecker
(Ludwig Boltzmann Institute for Leukemia Research, Vienna, Austria)

0713 SEQUENTIAL FISH-ANALYSES OF CIRCULATING CD34+-CELLS IN MDS - A SUITABLE METHOD FOR CYTOGENETIC MONITORING UNDER 5-AZACYTIDINE OR LENALIDOMIDE
F. Braulke, R. Steffens, C. Schuetze, K. Plischke, B. Chapuy, D. Haase
(Georg August University, Goettingen, Goettingen, Germany)

0714 RISK FACTORS FOR AML TRANSFORMATION AND MORTALITY IN TRANSFUSION-DEPENDENT DELETION 5Q MDS
A.F. List, A. Giagounidis, N. Brandenburg, K. Wride, A. Glasmacher,
U. Germing (University of South Florida, H. Lee Moffitt Cancer Center
and Research Institute, Tampa, Florida, USA)

0715 A STANDARDIZED APPROACH FOR THE ASSESSMENT OF BONE MARROW DYSPLASIA IMPROVES ON THE ACCURACY OF WHO CLASSIFICATION IN MYELODYSPLASTIC SYNDROMES
R. Invernizzi, E. Travaglino, C. Benatti, L. Malcovati, M.G. Della Porta,
M. Cazzola (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

0716 ANEMIA WITH RINGED SIDEROBLASTS ASSOCIATED WITH THROMBOCYTOSIS: CLINICAL AND ANALYTICAL FEATURES ACCORDING TO THE PRESENCE OR ABSENCE OF THE JAK2 V617F MUTATION
J.M. Raya, L. Arenillas, A. Domingo, E. Alonso, B. Bellosillo, M. Rozman,
G. Gutierrez, E. Luño, C. Sanzo, M.A. Piñan, G. Letamendi, M. Barbon,
M.L. Perez-Sirvent, J. Cervera, M.J. Muruzabal, J.I. Olalla, L. Yanez,
L. Garcia, A. Lemes, M.T. Molero, F. Milla, J.T. Navarro, A. Elosegi,
T. Hernandez-Santamaria, M.A. Cortes, M.L. Gonzalez-Ponte,
A. Villegas, M. Mateo, MA Duran, M Ardanaz, L Morabito, T Martin,
L Hernández-Nieto, T Vallespi, S Woessner, L Florensa (Hospital
Universitario de Canarias, La Laguna, Spain)

0717 THE IMMUNOPHENOTYPE OF DIFFERENT IMMATURE, MYELOID AND B-CELL LINEAGE COMMITTED CD34+ HEMATOPOIETIC CELLS ALLOWS DISCRIMINATION BETWEEN NORMAL/REACTIVE AND MYELODYSPLASTIC SYNDROME PRECURSORS
S. Matarraz Sudon, A. Lopez, S. Barrena, C. Fernandez, E. Jensen,
J. Flores, P. Barcena, A. Rasillo, J.M. Sayagues, M.L. Sanchez,
J.M. Hernandez Rivas, C. Salvador, N. Fernandez Mosteirin,
L. Perdiguer, A. Orfao (Centro de Investigación del Cancer, CSIC-USAL,
Salamanca, Spain)

0718 TELOMERE/CENTROMERE FLUORESCENCE IN-SITU HYBRIDIZATION (T/C-FISH) IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA ARISING FROM MYELODYSPLASTIC SYNDROME WITH COMPLEX KARYOTYPES
G. Göhring, K. Lange, B. Schlegelberger (Hannover Medical School,
Hannover, Germany)

0719 IMMUNOPHENOTYPIC DESCRIPTION OF PATIENTS WITH A MYELODYSPLASTIC SYNDROME AND 2 SPECIFIC CYTOGENETICS ABNORMALITIES: DELETION OF 5Q AND TRISOMY 8
M. Subirá, P. Font, E. Arranz, C. Serrano, R. Gonzalo, S. Castañón,
R. Mata, C. Soto, E. Olaso, A. Román, P. LLamas (Fundación Jiménez
Díaz, Madrid, Spain)

0720 BONE MARROW EXPRESSION OF CD33, CD34 AND CD117 FOR THE PROGNOSTIC ASSESSMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
G. Nador, A. Molteni, C. Cesana, M. Nichelatti, B. Scarpati, R. Cairoli,
L. Barbarano, M. Riva, A. Nosari, E. Morra (Department of Hematology,
Niguarda Ca’ Granda Hospital, Milan, Italy)

0721 FOUR-COLOR FLOW CYTOMETRY IS USEFUL IN DIAGNOSIS AND PREDICTING PROGNOSIS OF MYELODYSPLASTIC SYNDROME
C.H. Cha, C.J. Park, J.W. Chung, H.Y. Chung, Y.U. Cho, E.J. Seo,
H.S. Chi, J.H. Lee, J.H. Lee, K.H. Lee (Asan Medical Center, Seoul,
South-Korea)

0722 URINARY HEPCIDIN LEVELS ARE SUPPRESSED IN LOW GRADE MYELODYSPLASTIC SYNDROME AND MAY BE ASSOCIATED WITH MARKERS OF FUNCTIONAL IRON DEFICIENCY
T. Murphy, S. Mitra, C. Gleeson, P. Desmond, W. Swinkels
(Beaumont Hospital, Dublin, Ireland)

0723 EXTERNAL VALIDATION OF WHO CLASSIFICATION-BASED PROGNOSTIC SCORING SYSTEM(WPSS)
M.J. Park, J.H. Jang, C.W. Jung, K.H. Kim, S.J. Kim
(Samsung medical center, Seoul, South-Korea)

0724 IMMUNOLOGICAL BACKGROUND OF MDS, AN IMPACT ON PROGNOSIS AND PATHOGENESIS OF MDS
R. Neuwitova, V. Cukrova, J. Bartunkova, J. Karban, K. Siebertova,
A. Jonasova, J. Cermak, M. Belickova (University Hospital, Prague 2,
Czech Republic)

---

NON-HODGKIN'S LYMPHOMA - CLINICAL (AGGRESSIVE)

0760 OUTCOME OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA RELAPSING AFTER AN AUTOLOGOUS STEM CELL TRANSPLANT
J.M. Calvo-Villas, A. Martín, A. Pascual, I. Heras, J. De la Rubia,
R. Varela, M.J. Ramírez, R. Carrión, J. Sarra, M.J. Pascual,
M.J. Rodríguez-Salazar, E. Donato, S. Nistal, A. Salar, R. Andreu,
J. Sancho, J. Briones, R. Arranz, J.N. Rodríguez, E. Pardal, S. Duran,
M. Tapia, F.J. Peñalver, J.A. García-Marco, E. Conde, T. Bernal,
M.J. Requena, E. González-Barca, M.D. Caballero (Hospital General
de Lanzarote, Arrecife De Lanzarote, Spain)

0761 A PHASE II STUDY ON INTENSIVE ALL TYPE CHEMOTHERAPY WITH MINIMAL RESIDUAL DISEASE (MRD) ORIENTED POSTREMISSION STRATEGY IN ADULT PATIENTS WITH LYMPHOBLASTIC LYMPHOMA (PROTOCOL NILG-ALL NO. 09/00)
S.C. Cortelazzo, I.T. Intermesoli, O.E. Oldani, C.F. Ciceri, G. Rossi,
E. Pogliani, A. Gallamini, C. Romani, A. Cortelezzi, A. Rambaldi,
R. Bassan (Division of Hematology and BMT, Bolzano, Italy)

0762 RITUXIMAB WITH DOSE-DENSE MEGACEOP AND HIGH DOSE CHEMOTHERAPY (HDC) R-MAD WITH BEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN UNTREATED HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
A. Chiappella, A. Tucci, M.G. Cabras, A.M. Liberati, F. Salvi,
G. Ciccone, E. Angelucci, M. Badone, B. Botto, L. Falchi, C. Frairia,
R. Freilone, D. Novero, L. Orsucci, V. Pavone, E.M. Pogliani, U. Ricardi,
G. Rossi, D. Rota-Scalabrini, A. Levis, U. Vitolo (On the behalf of
GIMURELL, Hematology, San Giovanni Battista Hospital, Torino, Italy)

0763 IMPACT ON PROGNOSIS OF 18FDG-PET AFTER 4 CYCLES OF A CHOP OR CHOP-LIKE REGIMEN, WITH OR WITHOUT RITUXIMAB,IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, P. Gaulard, C. Gisselbrecht,
K. Belhadj, T. El Gnaoui, I. Gaillard, F. Kuhnowski, C. Lin, M. Meignan,
C. Haioun (CHU Henri Mondor, Créteil, France)

0764 RESULTS FROM A PHASE II TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA
H.W Peter, I.S Lossos, J. Tuscano, G. Justice, J.M. Vose, D. Pietronigro,
K. Takeshita, A. Ervin-Haynes, J.B. Zeldis, T. Habermann (New York
Medical Center, New York, United States of America)

0765 FLOW CYTOMETRY IS MORE SENSITIVE THAN CONVENTIONAL CYTOLOGY FOR THE IDENTIFICATION OF NEOPLASTIC INFILTRATION OF CEREBROSPINAL FLUID IN PATIENTS WITH AGGRESSIVE B-CELL NON-HODGKIN’S LYMPHOMA: RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY
S. Quijano, S. Quijano, A. López, J.M. Sancho, C. Panizo, P. Rodríguez
Otero, G. Deben, C. Castilla, E. Pérez-Ceballos, J.A. García-Vela,
M.C. Monteserín, A. Salar, N. Alonso-Vence, J. Arias, M. Pérez,
E. Domingo-Domenech, E. González-Barca, F.J. Peñalver, C. Poderós,
J. Plaza-Villa, M. Morado, M. Provencio, J. Garcia-Marco, C. Vallejo,
J. Arias, J. Briones, S. Ferrer, E. Gómez, J. Capote, C. Nicolás,
M. De la Cruz, A. Palacios, S. Fernández, A. Carmona, J.A. Hernández,
T. Molero, E. Romero-Picos, M.C. Mateos, M.J. Peñarrubia, D. Caballero,
E. Conde, A. Orfao (Centro de Investigación del Cáncer Universidad de
Salamanca, Salamanca, Spain)

0766 ABSOLUTE LYMPHOCYTE COUNT (ALC) IS A PROGNOSTIC FACTOR IN DIFFUSE- LARGE-B-CELL-LYMPHOMA (DLBCL)
M.C. Cox, F. Saltarelli, I. Nofroni, G. La Verde, R. Amodeo, C. Tatarelli,
B. Veggia, F. Tabacco, L. Portaro, M.A. Aloe-Spiriti, P. Cardelli, L. Ruco,
B. Monarca (A.O. Sant'Andrea, "La Sapienza" University, Rome, Italy)

0767 COMBINATION OF RITUXIMAB WITH INITIAL CHEMOTHERAPY IMPROVES THE OUTCOME OF PATIENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF A SINGLE INSTITUTION COHORT
A. Avigdor, T. Sirotkin, N. Shemtov, M. Berkowicz, Y. Davidovitz,
A. Kneller, I. Hardan, A. Shimoni, S. Apter, I. Ben-Bassat, A. Nagler
(The Chaim Sheba Medical Center, Tel-hashomer, Israel)

0768 THERAPEUTIC COMPLIANCE OF 6 CYCLES OF DOSE-DENSE IMMUNOCHEMOTHERAPY, R-CHOP-14 PLUS PEGFILGRASTIM, IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). PRELIMINARY RESULTS OF A PROSPECTIVE SPANISH TRIAL
E. González-Barca, M. Canales, A. Salar, M.J. Vidal, S. Ferrer, J. Bargay,
C. Grande, A. Oriol, J. García, S. Gardella, A. López, F.J. Tomás,
J. Briones, D. Caballero (Institut Catalá d'Oncología, Hospitalet De
Llobregar, Barcelona, Spain)

0770 EFFECTIVENESS OF RITUXIMAB FOR THE TREATMENT OF RELAPSED DIFFUSE LARGE B- CELL LYMPHOMA: RETROSPECTIVE ANALYSIS OF 407 CASES IN A SINGLE INSTITUTE
Y. Shimazu, N. Kenji, Y. Fujiwara, T. Ito, S. Morita, A. Sato, T. Sato,
T. Maeda, T. Onishi, C. Mizutani, F. Matsuyama, C. Tsukayama, Y. Ueda
(Kurashiki Central Hospital, Kurashiki, Japan)

0771 RITUXIMAB DOES NOT IMPROVE SURVIVAL OF PATIENTS TREATED WITH M/VACOP-B PLUS RADIOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A PHASE II STUDY OF INTERGRUPPO ITALIANO LINFOMI (IIL)
M. Martelli, V. Stefoni, E. Russo, G. Cabras, A. Rossi, E. Brusamolino,
A. Levis, B. Botto, V. Naso, E. Finolezzi, A. Di Rocco, R. Foà,
P.L. Zinzani (Hematology Institute, Roma, Italy)

0772 COMPARISON OF CLINICAL OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION BETWEEN PERIPHERAL T-CELL LYMPHOMAS AND DIFFUSE LARGE B-CELL LYMPHOMA
B.S. Sohn, D.H. Lee, S. Kim, J. Huh, C.W. Suh (Asan Medical Center,
Seoul, South-Korea)

0773 THE PREDICTION OF PROGNOSIS USING SEQUENTIAL QUANTITATIVE FDG-PET BEFORE AND AFTER 1 CYCLE OF CHEMOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
H.J. Kang, S.M. Lim, G.J. Cheon, C.W. Choi, S.S. Lee, B.Y. Ryoo,
B.H. Byun (Korea Cancer Center Hospital, Seoul, South-Korea)

0774 NODAL PERIPHERAL T-CELL LYMPHOMAS: TREATMENT OUTCOME AND PROGNOSTIC FACTORS
M.K. Angelopoulou, T.P. Vassilakopoulos, P. Tsirkinidis, S. Masouridis,
M. Moschoyiannis, P. Korkolopoulou, S. Kokoris, M. Siakantaris,
S. Sachanas, Z. Galani, E. Dimitriadou, C. Kalpadakis, K. Anargyrou,
M.N. Dimopoulou, M.-C. Kyrtsonis, E. Patsouris, G. Vaiopoulos,
G.A. Pangalis (National and Kapodistrian University of Athens, Athens,
Greece)

0775 BURKITT'S LYMPHOMA
A. Trabzi (Centre Pierre Marie Curie, Algiers, Algeria)

0776 THE ADDITION OF RITUXIMAB TO CHOP GREATLY IMPROVES THE OUTCOME OF PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): MATURE RESULTS OF A RETROSPECTIVE MULTICENTER STUDY
T. Vassilakopoulos, G.P Pangalis, Z. Galanis, S. Sahanas, A. Katsigiannis,
E. Vrakidou, C. Poziopoulos, N. Konstantinou, P. Repoussis,
M. Dimopoulou, S. Kokoris, E. Michali, E. Dimitriadou, S. Masouridis,
M. Siakantaris, F. Kontopidou, C. Kalpadakis, N.A. Viniou,
X. Yiakoumis, P. Korkolopoulou, M.C. Kyrtsonis, P. Panayiotidis,
P. Roussou, M. Angelopoulou (University of Athens, Laikon General
Hospital, Athens, Greece)

0777 A WORLDWIDE META-ANALYSIS ON THE USE OF ZIDOVUDINE AND INTERFERON-ALPHA FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA
A. Bazarbachi, O. Hermine, G. Panelatti, J.C. Ramos, P. Tortevoye,
Z. Otrock, G. Taylor, A. Gessain, W. Harrington, Y. Plumelle (American
University of Beirut Medical Center, Beirut, Lebanon)

---

NOVEL THERAPIES, DRUG RESISTANCE AND PHARMACOLOGY II

0778 TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT
C. Oberkanins, H. Puehringer, Q. Berisha, G. Klose, B. Schreyer,
W. Krugluger, R.M. Loreth (ViennaLab Diagnostics GmbH, Vienna, Austria)

0779 SILENCING OF SURVIVIN INDUCED BY A BCR-ABL/JAK2/STAT3 PATHWAY KILLS CML CELLS AND SENSITIZES IMATINIBRESISTANT CLONES TO THE EFFECT OF HYDROXYUREA
F. Stagno, S. Stella, E. Tirrò, E. Conte, F. Stagno, F. Di Raimondo,
A. Messina, P. Vigneri (Hematology Section, Catania, Italy)

0780 A CLONAL-EVOLUTION PATHWAY OF CML BLASTS TOWARD INCREASED CLONOGENICITY AND DRUG-RESISTANCE IS ASSOCIATED WITH UPREGULATION OF BCR-ABL, AP-1 TRANSCRIPTION FACTORS AND THE ABCB1 MULTIDRUG TRANSPORTER
H. G